

Variability in proteoglycan biosynthetic genes reveals new facets of heparan sulfates diversity. A systematic review and analysis

Mohand Ouidir Ouidja, Denis S.F. Biard^{a,b}, Sandrine Chantepie^a, Xavier Laffray^a, Gael Le Douaron^a, Minh-Bao Huynh^a, Nicolas Rebergue^a, Auriane Maïza^a, Karla Rubio^{a,c,1}, Oscar González-Velasco^d, Guillermo Barreto^{a,c,1}, Javier De Las Rivas^d, and Dulce Papy-Garcia^{a,*}

^a Univ Paris Est Creteil, Glycobiology, Cell Growth and Tissue Repair Research Unit (Gly-CRRET), Creteil, France. ^b - CEA, Institut de Biologie François Jacob (IBFJ), SEPIA, Université Paris-Saclay, Fontenay-aux-Roses, France. ^c Lung Cancer Epigenetic, Max-Planck-Institute for Heart and Lung Research, Bad Nauheim, Germany. ^d Bioinformatics and Functional Genomics Group, Cancer Research Center (CiC-IMBCC, CSIC/USAL/IBSAL), University of Salamanca (USAL), Salamanca, Spain.

¹ Present address: Université de Lorraine, CNRS, Laboratoire IMoPA, UMR 7365, F-54000 Nancy, France.

* **Correspondence to Dulce Papy-Garcia:** Gly-CRRET, University Paris Est Creteil, 61 Av General de Gaulle, 94010 Créteil, France. papy@u-pec.fr

Keywords: Systematic review and analysis, heparan sulfate proteoglycans, core protein, linker tetrasaccharide, heparan sulfate, biosynthetic genes, clinical variants, expression, sulfotransferases, stimuli.

Abstract


Proteoglycans are complex macromolecules formed of glycosaminoglycan chains covalently linked to core proteins through a linker tetrasaccharide common to heparan sulfate proteoglycans (HSPG) and chondroitin sulfate proteoglycans (CSPG). Biosynthesis of a single proteoglycan requires the expression of dozens of genes, which together create the large structural and functional diversity reflected by the numerous diseases or syndromes associated to their genetic variability. Among proteoglycans, HSPG are the most structurally and functionally complex. To decrease this complexity, we retrieved and linked information on pathogenic variants, polymorphism, expression, and literature databases for 50 genes involved in the biosynthesis of HSPG core proteins, heparan sulfate (HS) chains, and their linker tetrasaccharide. This resulted in a new gene organization and biosynthetic pathway representation in which the phenotypic continuum of disorders as linkeropathies and other pathologies could be predictable. Moreover, ubiquitous *NDST1*, *GLCE*, *HS2ST1*, and *HS6ST1* appeared to generate ubiquitous heparan sulfate (HS) sequences essential for normal development and homeostasis, whereas the tissue restricted *NDST2-4*, *HS6ST2-3*, and *HS3ST1-6* appeared to generate specialized HS sequences mainly involved in responsiveness to stimuli. Supported by data on genetic polymorphism and clinical variants, we afford a new vision of HSPG involvement in homeostasis, disease, vulnerability to disease, and behavioral disorders.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

35 1. Introduction

36 Proteoglycans are a family of macromolecules involved in virtually all aspects of cell biology and
 37 physiology¹. These complex molecules consist in a core protein carrying one or several
 38 glycosaminoglycan (GAG) chains, either chondroitin sulfates (CS), heparan sulfates (HS), keratan
 39 sulfates (KS), or combinations of them. In HS proteoglycans (HSPG) and CS proteoglycans (CSPG),
 40 the glycanic chain is connected to their core proteins through a common GAG-core protein linker
 41 tetrasaccharide (GAG-CP) (Fig. 1)¹⁻³. Both the identity of the core protein and the structure of the
 42 glycanic chain confer to proteoglycans a great functional diversity, as reflected by the multiplicity of
 43 diseases or syndromes resulting from defects on genes coding for their biosynthetic machinery.
 44 Among proteoglycans, HS proteoglycans (HSPG) display the greater structural and functional
 45 diversity. This is principally due to the diversity and differential expression of the numerous genes
 46 required for their synthesis (Fig. 1). Interestingly, whereas various of these genes are essential for
 47 normal development and homeostasis, several others are not, suggesting that some, but not all,
 48 HSPG play essential biological roles depending on the core protein and associated HS chains
 49 generated in each tissue and cell by its HSPG biosynthetic machinery.

50 The biosynthesis of HSPG starts in the endoplasmic reticulum with the production of the core protein
 51 coded by a single gene (for instance *HSPG2*, *AGR*, *COLXVIIA*, *GPCs*, or *SDCs* that code for full
 52 time HSPG core proteins). At the Golgi, the core protein is glycosylated to first form the GAG-CP
 53 linker tetrasaccharide. This requires the expression of several genes coding for different enzymes
 54 including glycosyltransferases (*XYLT1*, *XYLT2*, *B4GALT7*, *B3GALT6*, *B3GAT3*)^{4,5}, kinases
 55 (*FAM20B*)⁶, phosphatases (*PXYLP1*)⁷, and nucleosidases (*CANT1*)⁸, as well as nucleoside
 56 transporters (*SCL26A2*, *SLC35A2*, and *SLC35A3*)⁹ and ion transporters (*SLC10A7*)¹⁰ (Fig. 1).



57 **Fig. 1. Schematic representation of a HSPG and their biosynthetic genes.** HSPG are made of a core protein
 58 (CP) carrying a glycosaminoglycan-CP linker tetrasaccharide (GAG-CP linker) in which either heparan sulfate (HS)
 59 or chondroitin sulfate (CS) chains are elongated. The HS chain is formed by constitutive disaccharides composed
 60 of a uronic acid (GlcA or IdoA) and a glucosamine (GlcNAc, or GlcNS) carrying different sulfation and IdoA contents.
 61 NS domains carry high *N*-sulfation and IdoA levels; NA/NS domains carry intermediary *N*-sulfation, *N*-acetylation,
 62 and IdoA levels; NA domains are not sulfated and carry not IdoA. The GAG-CP linker biosynthetic genes are
 63 common to HSPG and CSPG biosynthetic machineries.

64 After formation of the GAG-CP linker, HS chain initiation starts through action of EXTL3 (coded by
65 *EXTL3*), which adds a *N*-acetyl glucosamine (GlcNAc) to the non-reducing end of the GAG-CP linker.
66 HS chain elongation continue by sequential addition of GlcA and GlcNAc catalyzed by EXT1/EXT2
67 (coded by *EXT1* and *EXT2*). During chain elongation, epimerization of glucuronic acid (GlcA) into
68 iduronic acid (IdoA) is then carried by C5 epimerase (coded by *GLCE*)¹¹ and sulfation occurs at
69 different position of the uronic acid and glucosamine residues. Sulfation of IdoA is assured by 2-*O*-
70 sulfotransferase (*HS2ST1*), whereas sulfation of GlcNAc is assured by *N*-deacetyl-*N*-
71 sulfotransferases (coded by *NDST1*, *NDST2*, *NDST3*, or *NDST4*), 6-*O*-sulfotransferases (coded by
72 *HS6ST1*, *HS6ST2*, or *HS6ST3*), and 3-*O*-sulfotransferases (coded by *HS3ST1*, *HS3ST2*,
73 *HS3ST3A1*, *HS3ST3B1*, *HS3ST4*, *HS3ST5*, or *HS3ST6*)^{3,12}. During biosynthesis, the HS chain
74 elongation can be stopped by the unproductive glycosyltransferases EXTL1 or EXTL2 (coded by
75 *EXTL2* or *EXTL1*)¹³, whereas after secretion of the HSPG at the extracellular space 6-*O*-sulfatases
76 SULF1 and SULF2 (coded by *SULF1* and *SULF2*) and heparanase (coded by *HPSE*) can modify
77 the HS chain structures¹⁴⁻¹⁶. Globally, this process leads to formation of different HS structural
78 domains^{3,17}. 'NA' domains carry unsulfated *N*-acetylated sequences, 'NA/NS' domains carry HS
79 sequences with intermediary levels of sulfation and IdoA, and 'NS' domains carry high levels of
80 sulfation and IdoA^{3,17} (Fig. 1).

81 Regardless of their structural diversity, HS are frequently referred as a single ubiquitous molecule,
82 possibly because their structural characterization is highly complex and yet beyond reach. Here, as
83 an approach to reduce HSPG complexity, we propose a new strategy based in a PRISMA¹⁸
84 systematic review and analysis of well established pathogenic variants and emerging genetic wide
85 association studies (GWAS) linking HSPG biosynthetic machinery gene variability to disease,
86 susceptibility to disease, altered response to instigating stimuli, or altered behaviors. To confirm the
87 documented clinical variants and traits in human, we compared them to the phenotypes of
88 corresponding gene null mouse, when available. Expression patterns in different organs or tissues
89 were retrieved from gene expression databases and information on structural features, including
90 substrate specificities for enzymes, or protein-protein interactions for core proteins and other
91 biosynthetic proteins, were reviewed following the PRISMA guidelines¹⁸. Association of this body of
92 information resulted in a new HSPG vision that gives a better understanding of the involvement of
93 each biosynthetic gene in the generation of HS sequences carrying structures that can play either
94 ubiquitous or specialized roles in the maintain of tissue homeostasis, disease, behavior disorders,
95 proper tissue response to instigating stimuli, and tissue specific vulnerability to disease.

96 **2. Methods**

97 Guidelines for Systematic Reviews and Meta-Analyses (PRISMA 2020)¹⁸ were followed to setup a
98 step-wise method (Fig. 2) for selecting and filtering research items on 50 genes directly involved in
99 the biosynthesis of HSPG (Table S1). For each HSPG biosynthetic gene, research items were

100 organized to screen clinical variants, single nucleotide polymorphism (SNP), expression levels in
101 different organs of the human body, and literature records databases on substrate selectivities and
102 protein-protein interactions.


103 **2.1. Search in clinical variants and SNP databases**

104 For each human gene (Table S1), clinical variants and SNP public databases accessible without
105 restriction were consulted by using gene names previously confirmed by MeSH (Medical Subject
106 Headings: <https://www.ncbi.nlm.nih.gov/mesh/>). Data on the impact of gene variability in health
107 status were obtained from three main databases (Fig. 2A): 1) the ClinVar archive (database ClinVar:
108 <https://www.ncbi.nlm.nih.gov/clinvar/intro/>), which gives information on correlations between genetic
109 variations and overt phenotypes or health status with history of interpretations, 2) the Orphanet
110 archive (Database Orphanet: <https://www.orpha.net/>), which considers clinical presentation based
111 on published scientific articles and expert reviews, and 3) the dbSNP archive (database:
112 <https://www.ncbi.nlm.nih.gov/snp/>), which is a free public archive for genetic variation within and
113 across different species. For clinical variants, only monogenic variants (indel, deletions, duplications,
114 insertions, and single nucleotide) were considered. Clinical significance was further confirmed in web
115 platforms including Online Mendelian Inheritance in Man (OMIM) (<https://www.omim.org/>) and the
116 Database of Genomic Variants Archive (DGVa database: <https://www.ebi.ac.uk/dgva/>). Information
117 on clinical variants overt phenotypes in human were confirmed by literature research on case reports
118 and on reports on the corresponding gene null mice (Methods section 2.3 and Fig. 2C-2D).

119 **2.2. Search in expression databases**

120 Information on the basal expression of the HSPG biosynthetic genes (Table S1) in different tissues
121 or organs of the healthy adult human body was retrieved from open access transcriptomic data bases
122 including: 1) the RNA-seq 32Uhlen project (database 32Uhlen:
123 <http://www.proteinatlas.org/humanproteome>), which analyzed 32 different tissues from 122 human
124 individuals, 2) the RNA-Seq CAGE (Cap Analysis of Gene Expression) in the RIKEN FANTOM5
125 project (database FANTOM5: <http://fantom.gsc.riken.jp/data/>), which analyzed several healthy adult
126 human tissues, and 3) the ENCODE strand-specific RNA-seq of 13 human tissues from Michael
127 Snyder's lab (Database ENCODE: <https://www.encodeproject.org/>). All these RNA-seq databases
128 are considered in the expression atlas (<http://www.ebi.ac.uk/gxa>)¹⁹, as they use standardized
129 methods that allow the determination of baseline gene expression across controlled biological
130 replicates checked for high quality (good quality raw files and good quality reference genome build
131 are available). The original raw and processed data files can be found in the ArrayExpress platform
132 (<https://www.ebi.ac.uk/arrayexpress/>), in which the raw single-channel microarray intensities were
133 normalized either using an oligo package from Bioconductor (Affymetrix data) or by quantile
134 normalization by the limma package (Agilent data). The data quality was assessed using the
135 arrayQualityMetrics package in R. Quality-trimmed reads were mapped to the latest version of the

136 reference genome from Ensembl using TopHat2. For each HSPG biosynthetic gene, the number of
 137 mapped reads per gene were summed (raw counts) using htseq-count and represented as average
 138 transcripts per million (TPM). When transcripts were detected in a tissue, regardless of their level of
 139 expression, a gene was considered to be basally expressed in that tissue. To illustrate gene
 140 expression, the best TPM value from the different databases was included in the analysis.



141 **Fig. 2. Schematic representation for collecting articles process following PRISMA¹⁸ recommendations. A)**
 142 **Clinical variants databases** were used to document the effect of HSPG biosynthetic genes variabilities in health status.
 143 **B)** Expression databases were used to document organs or tissues in which transcript for each of the genes can be
 144 detected under basal homeostasis (healthy status). **C)** Bibliographic databases were used to document reports on the
 145 effect of genetic variability in health status and to expression in organs and tissues. **D)** Bibliographic databases were
 146 also used to document proteins interactions between biosynthetic machinery proteins and substrates selectivities for
 147 biosynthetic enzymes.

148 2.3. Search in literature databases


149 PRISMA guidelines¹⁸ were used to carry two campaigns of literature research for each gene. The
 150 first campaign was performed to confirm information obtained from clinical variants databases
 151 (section 2.1 and Fig. 2A) by search of clinical variants case reports and reports on the corresponding
 152 gene null mouse (Fig. 2C). The second campaign was performed to retrieve information on each
 153 gene product functionally, including structural features for substrate specificity and selectivity for
 154 enzymes, and on protein-protein interactions for core proteins and other biosynthetic proteins (Fig.
 155 2D). Three literature search database thesauruses (PubMed, Scopus, and Science Direct) were
 156 employed for a systematic search facilitating an extensive inclusion (Fig. 2C and 2D). For each
 157 search engine, 2 subsets of pool keywords and Boolean logic were conducted for each of the 45
 158 genes. The first keywords subset (('gene symbol') AND (mutation OR SNP OR polymorphism OR

159 deficit OR disease OR "risk factor" OR "knockout mouse" OR "null mouse")) was used to review the
160 effect of genetic variability in health status (Fig. 2C). The second keywords and Boolean logic subset
161 was used to review the substrates specificities for enzymes or protein-protein interactions (('protein
162 name' OR 'protein symbol') AND (substrate OR "substrate structure" OR "substrate specificity" OR
163 interaction OR "interaction specificity")) (Fig. 2D). References were screened in accordance with title
164 and abstract. Only research articles and literature reviews were considered. Only reports in English
165 language were included. We did not specify a time frame in our literature search. An email alarm
166 system, on each database, was created for notifications on new publications related to the search
167 terms. All reports sorted in the three databases were exported to a common file for each gene in a
168 bibliographic management system (EndNote) and an automatic deduplication tool was applied to
169 discard duplicated reports. Then, reports in species other than human and mouse and reports in
170 cancer cell lines were systematically excluded, unless any example of SNP could be found in human.
171 A pilot user study was then conducted for examining full text reports and representative references
172 were selected and pooled in a single bibliographic management file using EndNote. The reference
173 list of the retrieved reports was also explored, articles non available were requested to authors via
174 email, otherwise references could not be included. Finally, our systematic review included a
175 synthesis of 254 peer-reviewed reports that were checked and review as representative of the full
176 retrieved data (200 reports cited in main text and additional 54 only cited in [Suppl. Inf.](#)).

177 **3. Results**

178 **3.1. Essential and non-essential HSPG biosynthetic genes**

179 A first clustering of the HSPG biosynthetic genes was performed on the bases of their requirement
180 for normal embryonic development and homeostasis, as reported by clinical variants databases.
181 Information on gene essentialness were confirmed by literature records in cases reports and/or from
182 reports on the corresponding gene null mouse (see extended review on genes in [Suppl. Inf.](#)). Genes
183 considered essential for normal embryonic development and homeostasis were those for which
184 genetic variability in human is causative of diseases or syndromes, and which corresponding null
185 mouse dies or shows overt phenotypes, consistent with that observed in clinical variants. Genes for
186 which genetic variability has not been reported as causative of human diseases or syndromes,
187 and/or for which the corresponding null mouse is viable, fertile, lives normally, and shows non-overt
188 phenotypes in the absence of stimuli, were considered non-essential for normal embryonic
189 development and homeostasis ([Suppl. Inf.](#)). However, most of the 'Non-essential' genes show some
190 genetic variability associations with altered responsiveness to stimuli, altered behaviors, or are
191 involved in vulnerability to altered conditions health conditions or behaviors ([Suppl. Inf.](#)). Based in
192 these criteria, 2 clusters of genes were formed, the first cluster is referred as 'Essential', and the
193 second as 'Non-essential' (Fig. 3). To avoid loss of clustering, HSPG biosynthetic genes involved in
194 tumor development and growth was not considered, as most HSPG are altered in cancer^{16,20,21}.



195 **Fig. 3. First clustering of HSPG genes depending on their requirement for normal development and**
 196 **homeostasis.** ‘Essential’ genes are those for which genetic variability in human is causative of diseases or syndromes
 197 and/or the corresponding null mouse dies or shows overt phenotypes consistent with what is observed in clinical
 198 variants. *They can show SNP. ‘Non-essential’ genes are those for which genetic variability has not been reported as
 199 causative of human diseases or syndromes and/or for which the corresponding null mouse is viable, fertile, lives
 200 normally, and shows non-overt phenotypes in the absence of stimuli, although many of them show SNP associations
 201 with altered responsiveness to stimuli, altered behaviors, or are involved in vulnerability to disease.

202 3.2. Ubiquitous and tissue restricted HSPG biosynthetic machinery genes

203 To get additional information on Essential and Non-essential HSPG biosynthetic genes in relation
 204 with their basal expression in human, genes were re-clustered depending on their expression in
 205 healthy organs or tissues, as documented in RNAseq databases (see Methods). Genes which
 206 transcripts were detectable in all analyzed organs were considered as ‘widely expressed’, whereas
 207 genes which expression was only detected in some tissues/organs were considered as ‘restrictedly
 208 expressed’ (Fig. 4 and Suppl. Inf.). This transcription-based re-clustering resulted in the HSPG
 209 biosynthetic genes organization in four groups of genes (Fig. 4): Group I, Group III, Group III, and
 210 Group IV, each of which is described below (simplified clustering is presented in Fig. 5). A review on
 211 each gene is detailed in Suppl. Inf.

212 3.2.1. Group I - Essential HSPG biosynthetic genes that are ubiquitously expressed

213 The Group I of HSPG biosynthetic genes clustered widely expressed genes that are essential for
 214 normal development and homeostasis (Fig. 4, simplified Fig. 5, and Suppl. Inf). This included genes
 215 coding for pericellular core proteins *HSPG2*²²⁻²⁵, *AGRN*²⁶⁻²⁹, and *COL18A1*³⁰⁻³², for some
 216 membrane-associated core proteins (*GPC3*³³⁻³⁵, *GPC4*^{36,37}, *GPC6*³⁸⁻⁴⁰), and for all the genes coding
 217 for the GAG-CP linker biosynthetic proteins, including glycosyl transferases (*XYLT1*^{41,42}, *XYLT2*⁴³,
 218 *B4GALT7*^{44,45}, *B3GALT6*^{46,47}, and *B3GAT3*⁴⁸), kinase *FAM20B* (*FAM20B*)⁴⁹, phosphatase
 219 (*PXYLP1*)⁷, ion or nucleotide transporters (*SLC10A7*¹⁰, *SLC26A2*⁵⁰, *SCL35A2*⁵¹, and *SCL35A3*^{9,52}),
 220 or other Golgian enzymes (*CANT1*)⁸. Importantly, Group I also clustered genes coding for the
 221 glycosyltransferases that assure HS chain initiation and elongation (*EXTL3*^{53,54}, *EXT1*⁵⁵, *EXT2*⁵⁶), for
 222 epimerase (*GLCE*)⁵⁷, and for three sulfotransferases (*NDST1*, *HS2ST1*, and *HS6ST1*)⁵⁸⁻⁶¹.
 223 Moreover, *SULF2*, which codes for one of the extracellular 6-O-sulfatase that generates biologically
 224 active HS sequences resulting from the cleavage of 6-O-sulfated groups^{14,62}, also clustered in Group

225 I. Altogether, the enzymes coded by the ubiquitous HS chain biosynthetic genes can then produce
226 ubiquitous HS sequences (uHS), which fine structures might depend on the expression levels of
227 each biosynthetic gene in each particular cell or tissue⁶³⁻⁶⁵, as well as in their transcriptional
228 regulation and translational control⁶⁶. Together, this body of data suggests that the Group I HSPG
229 biosynthetic machinery can, by itself, produce HSPG carrying biologically relevant HS sequences or
230 chains that are essential for normal development and homeostasis.

231 **3.2.2. Group II - Essential tissue restricted HSPG biosynthetic genes**



232 Group II clustered HSPG biosynthetic genes that, although essential, show tissue restricted
233 expression. Based in current available data and literature records, only *HPSE2* clustered in this
234 group (Fig. 4, Fig. 5, and Suppl. Inf). *HPSE2* codes for the enzymatically inactive heparanase 2.
235 Although it does not affect HS structures, heparanase 2 can bind to these polysaccharides with
236 higher affinity than the enzymatically active heparanase (Group III), avoiding its enzymatic action
237 and maintaining long HS chains in their biological environment^{67,68}. *HPSE2* is here reported as the
238 only gene in Group II, but the evolving literature and clinical reports might further enrich the number
239 of genes in this group.

240 **3.2.3. Group III - Non-essential HSPG biosynthetic genes that are ubiquitously expressed**

241 Group III clustered HSPG biosynthetic genes that although widely expressed are non-essential for
242 normal development and homeostasis (Fig. 4, Fig. 5, and Suppl. Inf.). However, genes in Group III
243 appeared to be required for appropriate tissue responsiveness to stimuli and, for several of them,
244 SNP is associated with increased or decreased vulnerability to disease, or to altered conditions or
245 behaviors (Suppl. Inf). Interestingly, all syndecans core proteins coding genes (*SDC1*⁶⁹⁻⁷¹, *SDC2*⁷²,
246 *SDC3*⁷³⁻⁷⁶, and *SDC4*⁷⁷⁻⁷⁹) and one glypican (*GPC1*^{80,81}) clustered in this group (Fig. 4). Concerning
247 the HS chain biosynthetic genes, none of these clustered in this group. Instead, Group III clustered
248 genes involved in the control of HS levels and quality, including *EXTL2*^{82,83}, *HPSE*⁶⁴⁻⁸⁶ and
249 *SULF1*^{70,87-89} (Fig. 5). Globally, data from GWAS, knockout mice, and literature research indicate
250 that genes in Group III are not essential for normal development and homeostasis but are required
251 for proper response to stimuli and or involved in vulnerability or resistance to disease and altered
252 behaviors.

253 **3.2.4. Group IV - Non-essential HSPG biosynthetic genes that are restrictedly expressed**


254 Group IV of HSPG biosynthetic machinery genes clustered all genes that are expressed in a tissue
255 restricted manner (Fig. 4) and which genetic variability is not causative of lethality or disease,
256 although SNP might be associated to resistance or vulnerability to pathologic conditions, to altered
257 response to stimuli, and to altered behaviors (Fig. 4, Fig. 5, and Suppl. Inf). Genes in Group IV
258 included those coding for two core proteins (*GPC2*⁹⁰⁻⁹² and *GPC5*⁹³⁻⁹⁵), three NDSTs (*NDST2*⁹⁶⁻⁹⁸,

GROUP	CHROMOSOME	GENE	TISSUE																							COMMENT					
			SMOOTH MUSCLE	SKIN	ADIPOSE TISSUE	URINARY BLADDER	OVARY	PROSTATE	TESTIS	ENDOMETRIUM	PLACENTA	LUNG	KIDNEY	PANCREAS	LIVER	HEART	STOMACH	SMALL INTESTINE	DUODENUM	COLON	LYMPH NODE	SPLEEN	ADRENAL GLAND	THYROID GLAND	SALIVARY GLAND		SKELETAL MUSCLE	BRAIN			
ESSENTIAL	I	uCP	1	HSPG2	116	31	140	62	20	51	16	72	63	55	19	6	5	31	27	18	17	29	19	43	28	59	18	14	6	Essential ubiquitous core proteins (uCP)	
			1	AGRN	7	15	14	18	4	23	21	15	16	57	48	8	4	4	17	16	12	18	5	15	3	30	19	2	10		
			21	COL18A1	25	36	35	38	99	56	26	49	37	26	80	23	128	14	15	29	34	24	18	66	41	22	12	4	10		
			X	GPC3	12	9	150	23	32	16	18	28	1114	220	79	10	2	12	9	7	4	7	6	7	49	15	7	0.6	18		
			X	GPC4	64	3	16	20	45	23	29	47	100	66	43	11	3	5	27	22	26	33	10	19	26	23	17	14	6		
			13	GPC6	22	1	20	40	27	23	5	9	2	13	18	1	28	5	13	10	6	20	1	7	8	6	3	0.5	16		
	I	uTetr	16	XYLT1	19	13	10	11	26	8	8	14	20	6	2	1	0.5	3	7	12	9	11	16	15	34	9	2	0.6	9	Essential ubiquitous GAG-CP linker (uTetr)	
			17	XYLT2	21	22	9	15	24	26	32	21	23	16	11	13	3	13	33	10	9	17	19	21	12	20	10	3	13		
			5	B4GALT7	10	22	10	11	16	16	17	13	15	14	14	28	4	13	9	9	10	13	19	18	12	17	13	3	19		
			1	FAM20B	69	38	48	53	69	51	28	82	53	68	14	32	19	29	35	30	24	36	36	40	65	74	17	11	43		
			1	B3GALT6	16	17	16	15	19	17	10	23	21	22	11	4	6	8	13	9	8	10	17	24	12	24	6	3	9		
			11	B3GAT3	20	38	17	27	38	44	37	42	48	34	14	21	8	9	27	27	26	16	65	52	30	39	18	2	20		
	I	uHS	8	EXTL3	29	17	11	17	16	13	23	22	24	14	7	3	3	21	7	6	6	7	9	16	24	18	6	6	24	Essential ubiquitous HS (uHS) elongation & sulfation 	
			11	EXT2	100	41	43	58	71	56	50	97	122	52	29	15	17	19	33	48	34	41	31	44	36	73	24	4	6		
			5	NDST1	58	80	55	42	59	36	56	36	36	119	27	16	32	28	16	31	22	27	19	124	53	86	41	9	21		
			15	GLCE	19	24	17	21	38	16	13	23	32	24	22	4	17	6	16	48	29	27	10	12	29	15	12	2	9		
			1	HS2ST1	22	21	15	28	35	25	25	32	18	25	17	5	14	7	14	20	16	19	31	31	53	35	7	2	18		
			2	HS6ST1	19	35	25	62	46	35	58	25	36	33	49	13	11	7	13	25	16	22	20	69	54	25	13	11	31		
	I	CQ	20	SULF2	199	24	34	75	214	33	37	202	60	26	33	7	28	15	20	21	30	46	50	30	13	30	7	4	8	Likely NA/NS domains	
	II	CQ	10	HPSE2	4	0.6	1	28	nd	19	5	15	3	5	2	nd	nd	nd	0.7	9	7	6	nd	nd	nd	0.7	nd	3	Essential tissue restricted QC		
NON-ESSENTIAL	III	uCP	2	GPC1	22	97	17	21	23	69	64	21	50	18	8	5	8	33	8	5	6	8	2	10	35	9	11	34	15	Non-essential ubiquitous core proteins (uCP)	
			2	SDC1	5	529	12	220	4	67	10	5	75	186	114	21	249	1	143	144	129	109	7	17	43	73	25	nd	11		
			8	SDC2	116	24	106	97	268	97	37	152	169	91	67	13	227	40	36	36	23	44	24	38	58	666	12	6	42		
			1	SDC3	186	22	49	71	33	61	15	72	40	57	10	7	15	19	19	28	20	24	46	263	190	31	13	3	87		
			20	SDC4	196	378	48	178	77	145	182	200	108	469	284	172	636	344	331	90	83	200	30	62	140	135	126	21	137		
	III	QC	1	EXTL2	26	11	12	22	38	29	22	38	47	17	11	8	17	6	8	7	7	10	8	17	43	22	6	3	19	Non-essential ubiquitous QC (uCQ)	
			8	SULF1	119	2	22	89	35	79	25	32	8	18	12	1	2	9	4	20	13	21	16	3	5	30	2	1	2		
			4	HPSE	4	15	4	8	9	2	6	12	5	11	2	0.8	2	0.5	4	6	3	11	11	16	8	3	4	nd	7		
	IV	rCP	7	GPC2	1	9	0.6	0.7	0.9	1	19	2	0.5	0.6	nd	nd	nd	0.9	nd	0.9	0.7	4	3	2	0.5	nd	0.9	nd	13	Non-essential tissue restricted core proteins (rCP)	
			13	GPC5	nd	nd	nd	nd	0.9	nd	16	nd	0.6	3	11	nd	0.9	0.5	nd	nd	nd	0.6	nd	nd	4	1	nd	nd	5		
		IV	rHS	10	NDST2	5	6	3	3	4	4	4	5	nd	6	1	1	0.9	0.8	2	2	2	2	7	8	3	4	2	nd	nd	Non-essential tissue restricted sulfation (rHS) 
				X	HS6ST2	6	0.5	0.9	6	45	6	8	14	35	1	21	2	nd	nd	nd	nd	nd	2	nd	nd	6	0.6	nd	3	1	
				13	HS6ST3	7	nd	0.9	18	nd	1	1	9	nd	2	1	nd	nd	2	0.5	0.9	nd	nd	nd	nd	6	nd	nd	40		
				4	HS3ST1	3	nd	1	12	61	3	3	5	2	3	2	nd	nd	4	2	2	3	3	4	3	1	1	1	nd	2	
				16	HS3ST2	2	7	4	2	9	2	3	0.8	2	16	nd	1	1	1	nd	nd	2	5	0.8	4	0.8	nd	nd	20		
				17	HS3ST3A1	0.5	nd	nd	0.8	7	6	0.7	0.9	6	0.7	1	nd	0.9	nd	0.8	0.9	0.7	0.6	4	13	3	nd	nd	nd	nd	
				17	HS3ST3B1	1	3	2	6	12	6	2	3	2	4	4	0.9	36	1	3	3	3	1	21	11	3	2	7	nd	1	
				4	NDST3	nd	nd	nd	nd	nd	nd	nd	nd	nd	0.5	nd	1	nd	0.5	nd	nd	nd	2	1	nd	nd	nd	nd	2		
4				NDST4	0.9	nd	nd	1	5	0.6	0.9	0.6	nd	nd	nd	nd	nd	nd	0.7	nd	nd	nd	nd	3	nd	nd	nd	1			
16				HS3ST4	nd	0.7	nd	0.6	nd	3	1	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	5	nd	nd	nd	nd	11			
6	HS3ST5	0.5	0.7	nd	0.7	nd	nd	0.5	nd	nd	0.8	nd	nd	nd	nd	nd	nd	nd	nd	nd	0.9	nd	nd	nd	2	4					
16	HS3ST6	nd	108	nd	5	nd	0.5	0.6	nd	3	0.7	nd	nd	0.8	nd	nd	nd	nd	0.6	nd	nd	nd	nd	nd	nd	nd					
IV	QC	1	EXTL1	4	2	nd	0.6	3	0.7	1	4	2	nd	nd	nd	3	nd	nd	nd	nd	0.7	4	3	1	nd	6	7	Non-essential tissue restricted QC			
REFERENCE GENES	12	GAPDH	1854	1009	558	1741	686	974	768	739	1763	577	831	177	600	1989	599	1205	1201	1174	1248	775	2140	1105	532	6797	894	<div style="display: flex; justify-content: space-between;"> >100 TPM <1 TPM </div> <div style="display: flex; justify-content: space-between;"> 10-100 TPM Below cutoff </div> <div style="display: flex; justify-content: space-between;"> 1-10 TPM </div>			
7	ACTB	7777	1375	1836	4533	2306	2972	1113	5617	3463	4197	799	188	1257	426	2088	2521	1763	2267	7360	5164	1371	2631	846	176	1545					

259
260
261
262
263
264
265
266
267
268
269

Fig. 4. The human HSPG biosynthetic machinery genes organized by gene essentiality and expression levels. HSPG biosynthetic genes were first separated in 'Essential' or 'Non-essential' for normal development and homeostasis depending on their requirement for normal human development and homeostasis and/or the phenotype of the corresponding gene null mouse (Suppl. Inf). Then, genes were re-clustered depending on their expression (transcript per million TPM) in a variety of human organs or tissues, as documented from RNAseq databases (FANTOM5: <http://fantom.gsc.riken.jp/data/>; ENCODE: <https://www.encodeproject.org/>; and 32Uhlen: <http://www.proteinatlas.org/humanproteome/tissue+specific>). Genes were organized in 4 main groups depending on their basal expression levels in adult human. CQ stands for 'Quality Control' that can arrest HS elongation during synthesis or remodel HS structure after secretion to the extracellular space. Ion and nucleotide transporters coding genes are not included.

270 *NDST3*⁹⁹⁻¹⁰¹, and *NDST4*^{102,103}), two HS6STs (*HS6ST2*^{104,105}, *HS6ST3*^{106,107}), all HS3STs
 271 (*HS3ST1*¹⁰⁸⁻¹¹⁰, *HS3ST2*^{111,112}, *HS3ST3A1*¹¹³⁻¹¹⁵, *HS3ST3B1*¹¹⁵, *HS3ST4*¹¹⁶, *HS3ST5*¹¹⁷, and
 272 *HS3ST6*^{118,119}), and one HS levels regulating genes (*EXTL1*¹²⁰). Based in current available data and
 273 literature records, it appeared that, at least in the absence of instigating stimuli, these genes are non-
 274 causative of disease and are not essential for normal development and homeostasis (Supp. Inf).
 275 Accordingly, their corresponding gene null mice, when available, develop normally, are fertile, and
 276 show non deleterious phenotypes (Supp. Inf). Depending on the gene, mice can show inappropriate
 277 response to instigating stimuli during processes including wound healing, angiogenesis,
 278 inflammation, immunity, infection, and response to neurological stimuli leading to altered adaptive
 279 behaviors (as alertness and satiety during feeding, and response to stress) (Suppl. Inf.). Moreover,
 280 SNP in Group IV genes, along or in combination with SNP in other loci, have been associated to
 281 vulnerability or resistance to diseases, to infection, and to impaired angiogenesis, inflammation,
 282 immunological response, altered behaviors, etc. (Fig. 3 and Suppl. Inf.). It is to note that all the HS
 283 sulfotransferases coding genes that did not cluster in Group I clustered in this group, including
 284 *NDST2*, *HS6ST2*, *HS6ST3*, and all *HS3STs*. Thus, based in information from knockout mice, GWAS
 285 data, and literature research, it appeared that the tissue restricted rHS sequences are those required
 286 for appropriate adaptive behaviors and responsiveness to stimuli in tissues in which each gene is
 287 specifically expressed.



288 **Fig. 5. Simplified organization of the HSPG biosynthetic machinery genes.** After a first clustering in 'Essential'
 289 or 'Non-Essential', HSPG biosynthetic genes were clustered depending on whether they show restricted expression
 290 or wide expression in human tissues under basal physiologic conditions. This dual organization allowed formation
 291 of four groups of genes: **Group I** integrates Essential and widely expressed genes coding for ubiquitous HSPG core
 292 proteins (uCP), ubiquitous GAG-CP linker tetrasaccharide (uTetr), and ubiquitous HS sulfate (uHS) biosynthetic
 293 enzymes and transporters. **Group II** integrates an Essential and tissue-restricted gene involved in the control of
 294 post-synthetic HS modifications (indicated as rQC, for tissue restricted quality control). **Group III** integrates 'Non-
 295 essential widely expressed genes' coding for ubiquitous HSPG core proteins (uCP) and widely expressed genes
 296 involved in HS post-synthetic modifications (uQC). **Group IV** integrates 'Non-essential restrictedly expressed
 297 genes' coding for tissue restricted core proteins (rCP), tissue restricted HS (rHS) biosynthetic enzymes, and tissue
 298 restricted genes involved in post-synthetic modifications (indicated as rQC, for tissue restricted quality control).

299 **3.3. Functional aspects of the HSPG core proteins**

300 **3.3.1. Essential pericellular core proteins**

301 Pericellular HSPG are essential constituents of basement membranes, the highly specialized
302 extracellular matrices that tie the epithelium to connective, endothelial, muscular, neuronal, and other
303 tissues¹²¹. The main pericellular HSPG core proteins are perlecan, agrin, and collagen 18,
304 respectively coded by *HSPG2*, *AGRN*, and *COL18A1*, which clustered in Group I (Table 1, Fig. 5,
305 and Suppl. Inf.). Perlecan is mainly expressed in skeletal, musculoskeletal, and cardiovascular
306 basement membranes^{23,122}. Hence, *HSPG2* variants affect these tissues with severities that depend
307 on the variant, as observed in Stuve-Wiedemann, Schwartz–Jampel and lethal Kniest-Like
308 syndromes^{23,25}, which traits are recapitulated in the *Hspg2*^{-/-} mouse²². Similarly, clinical variants in
309 *AGRN*, which codes for the agrin core protein characteristically expressed in neuromuscular
310 junctions¹²², result in a myasthenic syndrome, recapitulated in the *Agrn*^{-/-} mouse^{27,29}. Collagen XVIII
311 additionally supports basement membranes in some tissues³², as suggested by the traits observed
312 in *COL18A1* variants that lead to eye defects, occipital encephalocele (Knobloch syndrome), and
313 other overt phenotypes recapitulated in the *Col18a1*^{-/-} mouse^{30,31}. In addition to the importance of
314 pathogenic variants, SNP has been associated with risk to altered health condition or disease (Table
315 1, Fig. 3). For instance, *HSPG2* SNP has been associated with tardive dyskinesia¹²³ whereas
316 *COL18A1* SNP has been associated with pelvic organ prolapse¹²⁴. Globally, these data confirm the
317 essentialness of ubiquitous pericellular HSPG core proteins, and the importance of their likely-
318 ubiquitous HS chains, in the pericellular matrix organization¹.

319 **3.3.2. Essential cell membrane-associated core proteins**

320 Among HSPG membrane-associated core proteins coding genes, only *GPC3*, *GPC4*, and *GPC6*
321 clustered in Group I (Table 1, Fig. 5, and Suppl. Inf.). By keeping the HS chains very close to cell
322 membranes, glypicans are known to bring HS binding proteins near to their high affinity receptors¹²⁵.
323 Proteins requiring this proximity includes fibroblast growth factors, bone morphogenetic proteins,
324 wnts, hedgehogs, and several other proteins involved in cell signaling¹²⁵. Among *GPCs* pathogenic
325 variants, those in *GPC3* are the most severe, as shown by pre- and post-natal overgrowth with
326 skeletal, visceral, and neurological abnormalities observed in the X-linked Simpson-Golabi-Behmel
327 syndrome resulting from *GPC3* variability³⁴ and recapitulated in the *Gpc3*^{-/-} mice³³. Similar traits are
328 observed in *GPC4* variants responsible of Keipert syndrome³⁶, characterized by craniofacial and
329 digital abnormalities, deafness, and synaptic impairment, and in *GPC6* variants responsible of
330 omodysplasia-1³⁷ with facial dysmorphism, short stature, and shortened limbs, recapitulated in the
331 knockout mice³⁹. In addition to pathogenic genetic variability, SNP in *GPC4* and *GPC6* has been
332 associated to risk to altered conditions (Table 1 and Suppl. Inf). These data confirm the essentialness
333 of the ubiquitous *GPC3*, *GPC4*, *GPC6* in normal development and homeostasis and suggest that

334
335

Table 1. Genes coding for ubiquitous and tissue restricted HSPG core proteins. Genes are organized based on their expression in human tissues and traits of their clinical variants and/or phenotype of null mice.

	Gene	Impact of genetic variants in human	Phenotype of the null mouse	Most affected organs or tissues	Ref.
GROUP I Essential Widely expressed	<i>HSPG2</i>	From mild to lethal diseases: Lethal Kniest-like syndrome, Schwartz Jampel syndrome type 1, Stuve-Wiedemann syndrome, dyssegmental dysplasia of Silverman-Handmaker type (various degrees of bone dysplasia, cardiovascular and pulmonary defects, myotonia, hyperthermia...). SNP associations with tardive dyskinesia and intracranial aneurysm.	Embryonic lethality (E10-12) with severe chondrodysplasia, defective skeletal and cephalic development.	Cartilage, bone, bone marrow, cardiac muscle, brain, vasculature, etc.	22-25, 123
	<i>AGRN</i>	Congenital myasthenic syndrome with distal muscle weakness and atrophy with or without synaptic dysfunction. SNP associations with myasthenia gravis.	Embryonic lethality or die at birth due to respiratory failure, altered growth plate, central nervous system defects, and other defects.	Neuromuscular junctions, muscle, brain, growth plate.	26,27, 29,126
	<i>COL18A1</i>	Knobloch syndrome (severe eye and encephalocele defects). SNP association with pelvic organ prolapse.	Viable but with defects in the vasculature, ocular tissue, kidney proximal tubules, heart valves, epidermis, choroid plexus.	Eyes, kidney, heart, vasculature, brain, and epidermis.	30- 32,124, 127
	<i>GPC3</i>	Simpson-Golabi-Behmel syndrome (pre/post-natal overgrowth, skeletal, facial, visceral, neurological anomalies). Wilms tumor (nephroblastoma).	Perinatally die with kidney and lung dysplasia, cystic kidneys, etc. Recapitulates Simpson-Golabi-Behmel syndrome.	Bone, brain, kidney, lung, muscle, etc.	33,34
	<i>GPC4</i>	Keipert Syndrome (craniofacial and digital abnormalities, cognitive impairment, deafness, etc.). SNP association with autism spectrum disorders.	Craniofacial and digital abnormalities, behavioral alterations.	Brain, cranial bone, limb, hearing.	36,37
	<i>GPC6</i>	Omodysplasia (facial dysmorphism, short stature, shortened limbs...). SNP association with osteoporosis and multiple sclerosis.	Die at birth with severe facial dysmorphism and short bones.	Skeleton, facial bones.	38-40
GROUP III Non-essential Widely expressed	<i>GPC1</i>	No pathogenic variants reported. SNP association with risk of schizophrenia and biliary atresia.	Viable, fertile, healthy. However, slightly reduced brain size.	Brain.	80,81, 129
	<i>SDC1</i>	No pathogenic variants reported. SNP association with risk of coronary plaque in patients with coronary artery disease and risk of biliary atresia.	Viable, fertile, and healthy. However, altered response to stimuli during wound healing, inflammation, fibrosis, re-vascularization, infection...	Several tissues, altered response to instigating agents and angiogenesis.	69,70, 130
	<i>SDC2</i>	No pathogenic variants reported. SNP association with risk of posttraumatic stress disorder.	Mouse has not been generated. However, altered adaptive responses during tissue recovery after injury (fibrosis, inflammation).	Several tissues, altered response to instigating agents and angiogenesis.	72,130- 132
	<i>SDC3</i>	No pathogenic variants reported. SNP association with resistance to obesity and risk to metabolic syndrome and female hyperandrogenism.	Viable, fertile, and healthy. However, altered resistance to obesity and altered feeding behavior.	Brain, immune and adrenal systems.	73-76, 130,133
	<i>SDC4</i>	No pathogenic variants reported. SNP association with miss-regulation of whole-body energy metabolism and with longevity and lipid profile in healthy elderly.	Viable, fertile, and healthy life. However, altered reactivity to stimuli related to wound healing.	Several tissues: altered response to instigating agents and angiogenesis.	77,79, 134
GROUP IV Non-essential Restricted expression	<i>GPC2</i>	No pathogenic variants reported. SNP as part of polygenic risk suggestive of Alzheimer's disease.	Mouse has not been generated. However, transcript and protein levels increase when neurogenesis is stimulated in the adult mice brain and decrease when neurogenesis is ablated.	Brain.	91,128
	<i>GPC5</i>	No pathogenic variants reported. SNP association with risk for multiple sclerosis, autoimmune thyroid disease, and acquired nephrotic syndrome.	Mouse has not been generated.	Kidney and testis.	93-95

336 glypican, at least glypicans 3, 4 and 6, are the main HSPG that carry the HS involved in essential
337 cell signaling. Whether these HS are made by the also ubiquitous HS biosynthetic genes is unknown.

338 **3.3.3. Non-essential cell membrane-associated HSPG core proteins**

339 Excepting the essential *GPC3*, *GPC4*, *GPC6*, all other cell membrane-associated core proteins
340 coding genes (*GPC1*, *GPC2*, *GPC5*, *SDC1*, *SDC2*, *SDC3*, and *SDC4*) clustered in Groups III and
341 IV, both characterized for being non-essential for normal development but required for appropriated
342 response to stimuli, as during wound healing, angiogenesis, inflammation, immune response, normal
343 behaviors, etc. (Table 1, Fig. 5, and Supp. Inf.). For instance, SNP in *GPC1* loci was associated to
344 biliary atresia⁸⁰ and schizophrenia⁸¹, whereas *GPC2*, expressed in brain (Fig. 4) was involved in
345 proper response to neurogenic stimuli⁹¹. Similarly, the kidney, testis, and adrenal and thyroid glands
346 predominant *GPC5* (Fig. 4) was involved in podocyte response to injury and nephropathy
347 progression in type 2 diabetes patients¹³⁵ and SNP was associated with acquired nephrotic
348 syndrome, autoimmune thyroid disease, and risk for multiple sclerosis⁹³⁻⁹⁵. Similarly, syndecans are
349 required for appropriate tissue response to inflammation, infection, wound healing, angiogenesis,
350 neurological stimuli, etc.¹³⁶⁻¹³⁸. In agreement with the role of *SCD* genes in appropriate response to
351 stimuli, the *Sdc1*^{-/-} mouse showed altered capacity to recover from microbial infection or ischemia¹³⁹
352 and the *Sdc4*^{-/-} mouse showed delayed wound healing and impaired angiogenesis¹³⁴. Although the
353 *Sdc2*^{-/-} mouse has not yet been generated, syndecan 2 has been involved in fibrosis and
354 inflammation^{131,132}. Moreover, SNPs in some of these genes have been associated with risk to
355 develop diseases involving altered adaptative behaviors. For instance, *SDC1* polymorphism has
356 been associated with coronary plaque formation in coronary artery disease patients⁶⁹, with multiple
357 sclerosis⁷⁰, and with renal malfunction in adolescents with excess weight⁷¹. *SDC2* polymorphism has
358 been associated to posttraumatic stress disorders in post war veterans⁷². *SDC3* polymorphism has
359 been associate to satiety dysregulation and obesity^{74,76}, metabolic syndromes⁷³, and
360 schizophrenia⁷⁵. *SDC4* polymorphism was associated with risk of metabolic syndromes and obesity⁷⁷
361 and with longevity in healthy elderly Italian⁷⁹. Together, these data indicate that Group III and IV core
362 proteins, and possibly their HS chains, are required for appropriate responsiveness to stimuli and
363 adaptative behaviors rather than for the regulation of essential physiological processes.

364 **3.4. The GAG-CP-linker tetrasaccharide pathway first assures HSPG over CSPG** 365 **biosynthesis**

366 After synthesis of the core protein, the GAG-CP linker tetrasaccharide (Fig. 1) is synthesized by an
367 ubiquitous biosynthetic machinery involving several genes which, with exception of *XYLT1* and
368 *XYLT2*³, have not paralogue genes able to assure compensation. Because this machinery is
369 common to HSPG and CSPG, it can then be expected that defects in any of the ubiquitous GAG-CP

370 linker biosynthetic genes will affect production of both proteoglycans in all tissues. However, a
371 skeletal phenotype predominantly affecting CS is mainly observed in linkeropathies, the family of
372 diseases caused by variability in GAG-CP linker biosynthetic genes¹⁴⁰. Here, the integrative analysis
373 of clinical variants, gene expression, enzymes selectivities, and protein clusters data (Table 2, Fig.
374 4, and Supp. Inf.) indicates that the GAG-CP linker biosynthetic pathway is organized to
375 preferentially assure production of HSPG over that of CSPG (Fig. 6A), as detailed below.

376 3.4.1. The GAG-CP linker biosynthetic machinery

377 Biosynthesis of GAG-CP linker is initiated by addition of a xylose (Xyl) from UDP-Xyl to specific
378 serine residues in core proteins (Ser-CP)^{2,3}. This is assured by XYLT1 during development and by
379 both XYLT1 and XYLT2 after birth⁴² (Fig. 6A and Supp. Inf.). During development, *XYLT1* is highly
380 expressed by chondroblasts⁴², the cells that secrete a CSPG aggrecan rich matrix that forms the
381 cartilage template upon which bone is formed¹⁴¹. Indeed, as endochondral ossification of the
382 cartilage elements ensues, the expression of aggrecan by differentiating chondrocytes predominates
383 over expression of other proteoglycan core proteins¹⁴². Thus, to assure all proteoglycans
384 glycosylation in this high aggrecan content, XYLT1 binds to aggrecan core protein with lower affinity
385 than to other core proteins^{41,143}, including to the small leucine rich (SLRP) CSPG decorin that
386 stabilizes collagen fibrils in soft tissues, as skin and cornea¹⁴⁴. The higher affinity of XYLT1 for
387 decorin over aggrecan splits the GAG-CP linker biosynthetic pathway in a CSPG-decorin path and
388 a HSPG/CSPG-aggrecan path (Fig. 6A), in which rich aggrecan synthesis is assured by an abundant
389 substrate pool. Thus, during development, a defective *XYLT1* should primarily assure the decorin
390 path, principally affecting the CSPG-aggrecan path. Accordingly, *XYLT1* variability results in
391 Desbuquois dysplasia type 2 (known as Baratela–Scott syndrome)⁴¹, characterized by severe
392 skeletal growth retardation with multiple dislocations, joint laxity, advanced carpal ossification, with
393 no skin overt phenotypes, indicating that the CSPG-decorin path is unaffected (Table 2 and Supp.
394 Inf.). After birth, under physiologic conditions, *XYLT1* expression decreases and *XYLT2* is
395 expressed. XYLT2 shows similar affinity for both decorin and aggrecan core proteins, possibly
396 because after birth the abundant aggrecan synthesis is not any more required and HSPG and CSPG
397 syntheses need to be balanced. Although at different extents depending on the tissue, both XYLT1
398 and XYLT2 are expressed after birth (Fig. 4), Thus, defects in *XYLT2* should not affect development
399 and after birth they might be compensated by *XYLT1*, at least in some extent and in the tissues in
400 which the enzyme is expressed. Accordingly, during development *XYLT2* variants show no clinical
401 significance, but after birth they cause the post-developmental spondyloocular disorder
402 characterized by osteoporosis, cataract, hearing, and learning impairment^{43,135}.

403 On the continuation of the GAG-CP linker biosynthesis, B4GALT7 adds galactose (Gal) to Xyl-(Ser-
404 CP)¹⁴⁵ (Fig. 6A). B4GALT7 shows similar affinity for aggrecan and decorin core proteins, indicating
405 that defective B4GALT7 should affect both CSPG-decorin and HSPG/CSPG-aggrecan paths.
406 Accordingly, *B4GALT7* variants lead to B4GALT7-related Ehlers-Danlos syndrome

407 (spondylodysplastic EDS type 1)⁴⁵, which traits are like those caused by *XYLT1* mutations (CSPG-
 408 aggrecan path affected) with additional soft tissues overt phenotypes including hyperextensible, soft,
 409 thin, translucent, and doughy skin (CSPG-decorin path is affected) (Table 2 and Supp. Inf.)⁴⁵.

410 **Table 2. Ubiquitous GAG-CP linker tetrasaccharide biosynthetic genes.** Genes are organized based on
 411 their expression in human tissues and traits of their clinical variants and/or phenotype of null mice.

Gene	Impact of genetic variants in human	Phenotype of the null mouse	Most affected organs or tissues	Ref.
XYLT1	Desbuquois dysplasia (DBQD) type 2 (also known as Baratela–Scott syndrome), characterized by with short stature, joint laxity, advanced carpal ossification, mental retardation.	Non-available. However, a mouse carrying a <i>Xylt1</i> mutation shows chondrocyte premature maturation, early ossification, and dwarfism.	Connective and skeletal tissue, brain.	41,42
XYLT2	Spondyloocular syndrome (post-developmental osteoporosis, cataract, hearing and learning impairment).	Develops normally but show post-developmental defects in liver, biliary epithelial and renal cysts, low body weight, adipose tissue loss and lipodystrophy.	Skeletal, adipose, and connective tissues, liver, eye, bone, brain, kidney.	43,135, 147
B4GALT7	Spondylodysplastic Ehlers-Danlos Syndrome (spEDS)-progeroid type (connective and skeletal tissues with radioulnar synostosis) and Reunion Island Larsen-like syndrome (large spectrum).	Not reported.	Bone, cartilage, skin, brain, eye.	44,45, 148
FAM20B	Short limb dysplasia resembling XYLT1-related DBQD with mid-face and thoracic hypoplasia (leading to respiratory failure), very short stature, mesomelic limbs shortening and multiple joint dislocations.	Dies as embryo and shows severely stunted growth, multisystem organ hypoplasia, and delayed development of the skeletal system, eyes, lung, gastrointestinal tract, and liver.	Multiorgan hypoplasia, delayed growth and development.	49,149, 150
<i>B3GALT6</i>	spEDS progeroid type 2 (affecting connective and skeletal systems with sever skeletal affections), spondyloepimetaphyseal dysplasia with joint laxity, learning defects.	Not reported.	Bone, cartilage, skin tendons, ligaments, brain.	46,47
<i>B3GAT3</i>	Larsen-like syndrome with variable phenotypes similar to Antley-Bixler, Shprintzen-Goldberg, and Geroderma osteodysplastica syndromes.	Embryonic lethality before the 8-cell stage because failed cytokinesis.	Bone, cartilage, skin tendons, ligaments, heart, brain.	48
CANT1	Various skeletal phenotypes related to DBQD and Larsen syndrome with growth retardation, short extremities, progressive scoliosis, joint laxity, severe prenatal and postnatal growth retardation, etc.	Shows the continuum of skeletal dysplasia phenotypes including Desbuquois dysplasia and multiple epiphyseal dysplasia.	Skeletal and connective tissues, brain.	8,151
SLC10A7	Shortened long bones, growth plate and tooth enamel anomalies.	Short stature, amelogenesis imperfecta, and skeletal dysplasia with scoliosis.	Skeletal and connective tissues, brain.	10
PXYLP1	No pathogenic variants reported possibly because lethal. SNP association with good prognosis in cancer immunotherapies.	Not reported.	Unknown	152

GROUP I
Essential
Widely expressed


412

413

414

415 In the HSPG/CSPG-aggrecan path, the resultant Gal-Xyl-(Ser-CP) is then phosphorylated by
416 FAM20B to form Gal-Xyl(P)-(Ser-CP) (Fig. 6A), which is the preferred B3GALT6 substrate that
417 additionally promotes the HSPG/CSPG-aggrecan path. Indeed, in further steps of the GAG-CP linker
418 synthesis, phosphorylated products will become the preferred substrates that nourish the HSPG
419 path^{49,146}. This is consistent with the high lethality observed in the rare *FAM20B* clinical variants,
420 which show a phenotype like that observed in *XYLT1*-Desbuquois dysplasia (CSPG-aggrecan path
421 is affected) but additionally affecting many other organs⁴⁹ (HSPG path is affected) (Fig. 6A). In the
422 next step of the GAG-CP synthesis, B3GALT6 transfers a second Gal to Gal-Xyl(P)-(Ser-CP) in the
423 HSPG/CSPG-aggrecan path and to Gal-Xyl-(Ser-CP) in the CSPG-decorin path¹⁴⁵, nourishing both
424 pathways (Fig. 6). Again, the phosphorylated product is the preferred B3GAT3 substrate that will
425 then favor the HSPG path over the CSPG-aggrecan and CSPG-decorin paths (see below).
426 Accordingly, *B3GALT6* mutations lead to B3GALT6-related spondylodysplastic Ehlers-Danlos
427 syndrome (spEDS), characterized by bone dysplasia, joint laxity (CSPG-aggrecan path is affected),
428 and mild skin hyper elasticity⁴⁷ (CSPG-decorin path is affected) (Table 2). Subsequently, depending
429 on substrate pool levels, B3GAT3 will act alone or in association with PXYLP1, for which it shows a
430 high affinity. Indeed, when complexed to PXYLP1, for which B3GAT3 shows the high affinity, GlcA
431 addition occurs followed by immediate Xyl dephosphorylation to form GlcA-Gal-Gal-Xyl-(Ser-CP),
432 which is the preferred substrate for EXTL3 that starts HS chain initiation^{7,146,153} (Fig. 6A and 6B).
433 Abundance of GlcA-Gal-Gal-Xyl-(Ser-CP) substrate pool allows CSGALNACT1 action on substrates
434 that did not integrate the HS path. Moreover, in associating with B3GAT3 un-complexed PXYLP1,
435 CSGALNACT1 can also act in Gal-Gal-Xyl(P)-(Ser-CP), which is the preferred substrate for
436 CSGALNACT1, starting CS chain initiation^{7,146,153}. Thus, higher expression levels of B3GAT3
437 compared to PXYLP1 (Fig. 4) and high affinity between PXYLP1 and B3GAT3 can favor equilibrium
438 through the HS synthesis. PXYLP1 un-complexed B3GAT3 (Fig. 6A). Therefore, in defective *EXTL3*,
439 its substrate excess allows the initiation of CS chain synthesis by CSGALNACT1 along or in
440 association with PXYLP1^{146,153}, favoring aggrecan synthesis (Fig. 6A and 6B)^{7,146,153}. Thus, the
441 phosphorylated and non-phosphorylated substrate pools and the levels of expression of B3GAT3,
442 PXYLP1, XYLT3, and CSGALNACT1, at least, will participate to the selection of the proteoglycan
443 that will be preferentially elongated¹⁴⁶. Globally, based in literature data, clinical variants and
444 expression databases, our analysis indicate that the CSPG and HSPG overlapping paths can
445 concomitantly occur with crossed pathways, which preferences are driven by abundancy of
446 substrates pools, substrates selectivities, levels of expression, and protein-protein interactions. In
447 case of defective genes, the preferred maintain of the HSPG path is supported by the mixed skeletal
448 and soft tissue phenotypes observed in *B3GAT3* clinical variants responsible of Larsen, Antley-
449 Bixler, Shprintzen-Goldberg, Geroderma osteodysplastica, and spEDS⁴⁸ and other linkeropathies
450 (Tables 2 and 3).

451



452 **Fig. 6. Schematic representation of the HSPG biosynthetic pathway.** The HSPG path (brown arrows) overlaps
 453 with the CSPG-aggrecan path (marine blue arrows). The CSPG-decorin path (light blue arrows) is spliced from
 454 HSPG/CSPG path at early steps. Black arrows designate paths that stop GAG elongation. Arrow width designs
 455 preferred paths based in substrate preferences (see Gene review), wider arrows indicating preferred paths.
 456 Substrate pools guarantees maintenance of minor paths (narrow arrows). Dotted arrows indicate non-detailed
 457 steps. Green empty arrows indicate UDP-sugars or ion transport. Some nucleotide transporters or ion transports
 458 are represented. Ions as Ca²⁺, Mn²⁺ and/or Mg²⁺ are indicated when required for enzymatic activity. **A)** Biosynthesis
 459 of the GAG-CP linker tetrasaccharide common to HSPG and CSPG.), Excepting XYLT1 and XYLT2, all enzymes
 460 and transports are ubiquitously expressed during development (dev) and after birth (aft. birth). XYLT1 is highly
 461 expressed during development (↑↑dev) and its expression decreases aft. birth and preferentially binds to low
 462 molecular weight CSPG core proteins, as decorin (leading to favored CSPG-decorin path). XYLT2 is expressed aft.
 463 birth and shows similar binding to HSPG and CSPG core proteins (leading to both CSPG-decorin and HSPG/CSPG-
 464 aggrecan paths). Xyl is not phosphorylated in the CSPG-decorin path. **B)** Ubiquitously expressed enzymes drive
 465 the synthesis of ubiquitous HS sequences (uHS). **C)** Tissue restricted enzymes form HS sequences (rHS) likely
 466 during response to stimuli. rHS might contain high NS domains formed either from uHS or directly from unsulfated
 467 chains). **D)** Representative HS disaccharide indicating GlcA, IdoA and GlcN units and sulfation positions (in red).

468 **3.4.2. Other enzymes and transporters**

469 In addition to variability in GAG-CP linker biosynthetic genes, genetic variability in ion and nucleotide
470 transporters, or in other Golgian proteins that allow availability of sugar nucleotides and ions, can
471 dramatically alter the biosynthesis of the GAG-CP linker^{154,155}. For instance, the calcium activated
472 nucleotidase-1 (*CANT1*) hydrolyses the uridine diphosphate nucleoside (UDP), which inhibits
473 glycosyltransferases (as *XYLTs*)¹⁵⁵ (Fig. 6A). Accordingly, *CANT1* clinical variants lead to
474 Desbuquois dysplasia traits like those observed in *XYLT1* and *B4GAT7* variants^{8,151} (Table 2).
475 Because *CANT1* is calcium dependent, variants in the Ca²⁺ transporter *SLC10A7* result in skeletal
476 dysplasia with *CANT1* and *XYLT1* overlapping traits¹⁰ (Table 2). Similarly, variants in genes coding
477 for sulfate ion transporters (*SLC26A2*)¹⁵⁶, nucleotide (UDP-GlcNAc and UDP-Gal) transporters
478 (*SCL35A2* and *SCL35A3*), or ions (Mg²⁺ and Mn²⁺) transporters required for proper enzymatic
479 activities at the Golgi (Fig. 6A), can result in linkeropathies-like phenotypes^{9,155,157}.

480 **3.5. Essential and non-essential HS sequences**

481 **3.5.1. Ubiquitous HS are essential for normal development and homeostasis**

482 After biosynthesis of the GAG-CP linker, formation of the HS chain starts by the action of the
483 glycosyltransferase *EXTL3*², which adds a GlcNAc residue to the dephosphorylated GlcA-Gal-Gal-
484 Xyl-(Ser-CP) product of *B3GAT3/PXYLP1* (Fig. 6B). *EXTL3* deficiency results in reduced HSPG and
485 increased CSPG levels, confirming that abundant GlcA-Gal-Gal-Xyl-(Ser-CP) and GlcA-Gal-Gal-
486 Xyl(P)-(Ser-CP) substrate pools respectively favor *CSGALNACT1* and *CSGALNACT1/PXYLP1*
487 activities, thus driving CS initiation (Fig. 6A). Accordingly, lack of *Extl3* in mice causes embryonic
488 lethality possibly due to the lack of HS chain synthesis. In human, biallelic mutations in
489 the *EXTL3* gene result in a neuro-immuno-skeletal dysplasia syndrome⁵⁴, suggesting an imbalanced
490 HSPG/CSPG-aggrecan paths with decreased HS synthesis and increased syntheses of CSPG
491 aggrecan and neurocan (Fig. 6A and 6B, Table 3, and Supp. Inf.). Following continuation of the HS
492 chain synthesis, the *EXT1/EXT2* hetero-oligomeric complex elongates the HS chain by alternated
493 addition GlcNAc and GlcA to the GlcNAc-GlcA-Gal-Gal-Xyl-(Ser-CP) substrate, which initiates HS
494 chain elongation² (Fig. 6B). In *Ext1/Ext2* depleted mice, lack of HS leads to gastrulation failure and
495 embryonic death^{55,56}, agreeing the essentialness of HS chains carried by proteoglycans. In human,
496 *EXT1* or *EXT2* variants lead to hereditary multiple exostoses (Table 3), characterized by the
497 formation of cartilage-capped bony outgrowths¹⁵⁸, suggestive of the accumulation of *EXT1/EXT2*
498 GlcNAc-GlcA-Gal-Gal-Xyl-(Ser-CP) substrate, which is the *EXTL3* product. Thus, this in turn results
499 in increased GlcA-Gal-Gal-Xyl-(Ser-CP) pool, which nourishes the CSPG-aggrecan path (Fig. 6A).
500 Thus, in the context of GlcA-Gal-Gal-Xyl-(Ser-CP) substrate pool excess, CSPG-aggrecan can be
501 accumulated in tissues in which its synthesis is rich, explaining the epiphyseal growth plates resulting
502 in cartilage-capped bony outgrowths. On the continuation of HS elongation, HS chain maturation is

503 assured by the ubiquitous NDST1, HS2ST, HS6ST1, and C5-epimerase (*GLCE*), which respectively
 504 assure basal *N*-deacetyl-*N*-sulfation, 2-*O*-sulfation, 6-*O*-sulfation, and GlcA/IdoA epimerization².
 505 Interestingly, NDST1 and HS6ST1 substrate specificities suggest that, in association with HS2ST
 506 and *GLCE*, these enzymes can form sequences carrying NA/NS domains^{59,159-163} (*Supp. Inf.*).
 507 Indeed, NDST1 can generate HS domains with lower level of *N*-sulfation than NDST2¹⁶⁴ while
 508 HS6ST1 shows higher selectivity for non-2-*O*-sulfated residues (hexA-GlcNS), as confirmed in the
 509 *Hs6st1* null mouse⁵⁹. According with their essentialness, uHS made of NA/NS domains might then
 510 be those that interact and regulate HBP required for normal development and homeostasis^{17,165}.
 511 Accordingly, *Ndst1*^{-/-}, *Hs2st1*^{-/-}, and *Glce*^{-/-} mice perinatally die with severe developmental
 512 abnormalities^{57,60,61}, and the *Hs6st1*^{-/-} mouse cannot thrive⁵⁹ (*Table 3*).

513 **Table 3. Ubiquitous heparan sulfates (uHS) biosynthetic genes.** Genes are organized based on their
 514 expression in human tissues and on clinical variants traits and/or phenotype of the corresponding null mice.

Gene	Impact of genetic variants in human	Phenotype of the null mouse	Most affected organs or tissues	Ref.
<i>EXTL3</i>	Severe autosomal recessive skeletal dysplasia, including epispondylo-metaphyseal dysplasia, with developmental delay, immunodeficiency, and neuromotor and brain development delay.	Embryonically lethal at around 9 days post-fecundation with HS non-detected and with over production of CS in chondrogenic tissues.	All tissues.	54,167
<i>EXT1</i>	Hereditary multiple exostoses (multiple cartilaginous tumors), scoliosis, seizures, macrocephaly, defects in pancreas, lung, heart, cornea, etc.	<i>Ext1</i> ^{-/-} <i>Ext2</i> ^{-/-} mice die at embryo due to gastrulation failure. <i>Ext1</i> ^{-/-} form several exostoses.	Cartilage and bone.	55,158
<i>EXT2</i>	Hereditary multiple exostoses (less severe than that caused by <i>EXT1</i>).	<i>Ext1</i> ^{-/-} <i>Ext2</i> ^{-/-} mouse dies at embryo due to gastrulation failure. <i>Ext1</i> ^{-/-} mouse forms several exostoses.	Cartilage and bone.	55,56, 158
<i>NDST1</i>	Compound heterozygous mutations cause developmental delays, muscular hypotonia, ataxia, history of seizures, intellectual disability, epilepsy, gastroesophageal reflux, minor malformation, etc. Partially compensated by NDST2 except in brain (expressing NDST3 and 4), and skeletal muscle.	<i>Ndst1</i> ^{-/-} perinatally dies by respiratory failure and shows skeletal, brain, and heart defects. Heterozygous mouse shows severe developmental defects of the forebrain and forebrain-derived structures.	Brain, lung, skeletal and heart muscles, stomach, etc.	58,61
<i>GLCE</i>	No pathogenic variants reported possibly because lethal. SNP associations with hypertension, and cerebrovascular events.	Neonatally lethal with severe developmental abnormalities on kidney, lung, skeleton, spleen, thymus, lymph node, etc.	Several organs: kidney, skeleton, thymus, lung, lymph node, spleen, etc.	11,57, 168
<i>HS2ST1</i>	No pathogenic variants reported possibly because lethal. SNP has been associated to n birds and pig has been associated with low metabolic rate and longevity in pigs and birds.	Neonatally lethal with onset of abnormalities after mid-gestation leading to traits including complete failure of kidney development.	Several tissues, particularly kidney.	60,169
<i>HS6ST1</i>	No pathogenic variants reported possibly because lethal. SNP association with delayed puberty and idiopathic hypogonadotrophic hypogonadism.	Lethal at late embryonic stages, with abnormalities in lung morphology, angiogenesis, and retinal axon guidance. If viable, mice showed growth retardation and lung defects.	Several organs: lung, kidney, cartilage, vascular system, reproduction organs, etc.	59

GROUP I
Essential
Widely expressed

516 Moreover, no pathogenic variants are known in human for *HS2ST1*, *HS6ST1*, or *GLCE*, possibly
517 because lethal. However, individuals with compound heterozygous *NDST1* mutations can survive,
518 although with brain and muscle overt phenotypes⁵⁸. This is possibly due to *NDST2* redundancy, as
519 *NDST2* is not expressed in brain and skeletal muscle (Fig. 4)^{58,166}. Together, these data support that
520 uHS sequences synthesized by the Group I HSPG biosynthetic machinery could be those which,
521 depending on their level of expression in each tissue, form HS sequences able to interact and
522 regulate the activities of heparin binding proteins that assure tissue basal functions and homeostasis,
523 as growth factors, morphogens, and other pericellular and cell membrane-associated proteins
524 centrally involved in normal development and homeostasis.

525 3.5.2. Non-essential HS in the appropriate response to stimuli

526 *NDST2*, *NDST3*, *NDST4*, *HS6ST2*, *HS6ST3*, and all *HS3STs*, are tissue restricted sulfotransferases
527 coded by genes clustered in Group IV (Fig. 4, Fig. 5, and Suppl. Inf). No pathogenic variants are
528 known for any of these genes and the corresponding knockout mice, when available, develops
529 normally, are fertile, and live healthy (Table 4, and Suppl. Inf.). Although it cannot be excluded that
530 absence of deleterious phenotypes can be due to compensation phenomena, polymorphisms in
531 most of these genes have been associated with resistance or risk to altered conditions affecting the
532 organs in which they are expressed (Tables 4, see Suppl. Inf.). For instance, in brain, SNP in *NDST3*
533 has been associated with risk of schizophrenia and bipolar disorders^{99,101}, SNP in *NDST4* has been
534 associated with reading difficulty and language impairment¹⁰², SNP in *HS6ST2* has been associated
535 with intellectual disability¹⁰⁵, SNP in *HS6ST3* has been associated with dysregulation of satiety^{101,106},
536 and SNP in *HS3ST1* has been associated with to Alzheimer's disease^{108,110}. Moreover, the
537 involvement of some of these genes in the appropriate response to neurological stimuli is starting to
538 be documented. For instance, the *Ndst3*^{-/-} mouse exhibited subtle impaired anxiety with not
539 compensatory effects from other *Ndst*¹⁰⁰ while *HS3ST2* expression was increased in the rat pineal
540 gland after adrenergic stimulation¹⁷⁰, indicating a role of these enzymes in adaptative neurological
541 functions.

542 In peripheral tissues, several polymorphisms have been associated, along or in combination with
543 other genes, with altered conditions or susceptibility to disease (Table 4). For instance in coronary
544 artery diseases (*HS3ST1*), ulcerative and Crohn's colitis (*HS3ST2*)¹¹¹, chronic obstructive pulmonary
545 disease (*HS3ST2*)¹¹², and hereditary angioedema (*HS3ST6*)¹¹⁹. The importance of these genes in
546 the regulation of response to stimuli is also supported by available knockout mice and biomedical
547 research. For instance, the *Hs3st1* null mouse showed a strong proinflammatory phenotype¹⁰⁹,
548 *HS3ST3B1* was shown to be involved in T lymphocytes activation¹⁷¹, *HS3ST3A1* expression was
549 found increased during normotensive and pre-eclamptic pregnancies¹¹³, and *NDST2* was essential
550 for mast cells responsiveness during inflammation and during innate and adaptive immunity toward
551 pathogens¹⁷². Moreover, 3-O-sulfated HS (3S-HS) are well known to increase susceptibility to

552 infection by pathogens¹². Accordingly, polymorphism in both *HS3ST3A1* and *HS3STB1* has been
 553 associated with risk to *P. falciparum* infection¹⁷³ and some 3S-HS structures trigger HSV infection¹².

554 **Table 4. Tissue restricted heparan sulfate (rHS) biosynthetic genes.** Genes are organized based on their
 555 expression in human tissues, traits of clinical variants, and/or phenotype of the corresponding null mice.

	Gene	Impact of genetic variants in human	Phenotype of the null mouse	Most affected organs or tissues	Ref.
GROUP IV Non-essential Partial restricted expression	<i>NDST2</i>	No pathogenic variants reported. SNP association with risk of coronary artery disease and chronic kidney disease.	Viable, healthy, and fertile. Mast cell shows decreased sulfation in HS.	Mast cells	176,177
	<i>HS6ST2</i>	No pathogenic variants reported. SNP association with risk of X-linked intellectual disability and myopia.	Viable, healthy, and fertile.	Brain and cartilage.	105
	<i>HS6ST3</i>	No pathogenic variants reported. SNP association with decreased risk to obesity and to increased diabetic retinopathy.	Not reported.	Brain, eye.	107,178
	<i>HS3ST1</i>	No pathogenic variants reported. SNP association with risk of arteriosclerosis, coronary artery diseases, and Alzheimer's disease.	Viable, healthy, and fertile but show proinflammatory phenotype when submitted to pathologic stimuli.	Vascular system and brain.	179,180
	<i>HS3ST2</i>	No pathogenic variants reported. Expression is increased in Alzheimer's disease. SNP association with risk of schizophrenia.	Viable, healthy, and fertile. Responds to adrenergic response to light stimuli.	Brain.	12,170, 181
	<i>HS3ST3A1</i>	No pathogenic variants reported. SNP association with risk of HSV1 and <i>P. falciparum</i> infection.	Not reported.	Vascular system.	173,182
	<i>HS3ST3B1</i>	No pathogenic variants reported. SNP association with risk of <i>P. falciparum</i> infection.	Not reported. But overexpression affects immunity (peripheral T lymphocytes and Jurkat T cells adaptive response to stimuli).	Immune system.	173,182, 183
GROUP IV Non-essential High restricted expression	<i>NDST3</i>	No pathogenic variants reported. SNP association with risk of mental disorders as schizophrenia and bipolar disorders.	Develop normally, are fertile, and show only subtle hematological and behavioral abnormalities, with reduced anxiety.	Brain.	99-101
	<i>NDST4</i>	No pathogenic variants reported. SNP association with risk of reading disability and language impairment.	No pathological outcomes, but some anomalies can be observed in histology images of the proximal colon, where the gene is not expressed.	In cartilage, brain, immune system.	102,103
	<i>HS3ST4</i>	No pathogenic variants reported. SNP association with risk of altered verbal declarative memory, age-related macular degeneration, schizophrenia, and Alzheimer's disease.	Not reported.	Brain.	116,117, 178,184
	<i>HS3ST5</i>	No pathogenic variants reported. SNP association with risk of intellectual disability and altered gray matter volume in schizophrenia.	Not reported.	Brain.	117,185
	<i>HS3ST6</i>	No pathogenic variants reported. SNP association with risk of altered response to stimuli that triggers angioedema.	Not reported.	Skin, vascular system.	118,119

556

557 3.5.3. HS chain remodeling and biosynthesis arrest

558 After biosynthesis, HSPG are secreted to the cell surface or to the pericellular space, where their
 559 HS chains can be remodeled by SULF1, SULF2¹⁴, and/or by heparanase¹⁵, which activity can be
 560 negatively regulated by the enzymatically inactive heparanase 2⁶⁷ (Table 5). Although no clinical
 561 variants are known for *SULF2*, the *Sulf2*^{-/-} mouse shows lethality¹⁴ (included in Group I), whereas in
 562 human, *HPSE2* variants result in pos-developmental syndromes (included in Group II), and other
 563 altered conditions (Suppl. Inf.)^{68,174,175}. This indicates that both SULF2 and HPSE2 are required for
 564 normal homeostasis and basal response to stimuli. The involvement of HPSE2 in response to stimuli
 565 was confirmed in the homozygous *Hpse2* gene trap mouse, which developed normally but showed
 566 deficient responses to chemical and electrical field stimulation and showed low weight gain after
 567 weaning and died early in life^{174,175}. In the other side, both *Sulf1*^{-/-} and *hpse*^{-/-} mice develop and live
 568 normally, are anatomically normal fertile, and show non overt phenotypes^{14,186} (included in Group
 569 III). Accordingly, non-pathogenic variants are known in human (Table 5). However, SNP has been
 570 associated with chronic graft-versus-host disease⁸⁴, supporting its clustering in Group III.
 571 Accordingly, as for other genes in Group III, nonpathogenic *SULF1* variants are known, but
 572 polymorphism has been associated to multiple sclerosis⁷⁰, fetus failure during *in vitro* fertilisation⁸⁸,
 573 and preeclampsia⁸⁹ (Table 5).

574 **Table 5. Genes coding for heparan sulfates remodeling enzymes.** Genes are organized based on their
 575 expression in human tissues, clinical variants traits, and/or phenotype of the corresponding null mice.

	Gene	Impact of genetic variants in human	Phenotype of the null mouse	Most affected organs or tissues	Ref
GROUP I Essential Widely expressed	<i>SULF2</i>	No pathogenic variants reported. SNP associations with risk to altered regulation of lipoprotein metabolism, fasting, and postprandial triglycerides clearance.	Significant lethality with reduction in brain mass during neuronal development with some kidney, lung, and skeletal defects.	Various, including brain, kidney, lung, skeletal tissue, etc.	168,187-189
GROUP II Essential restricted expression	<i>HPSE2</i>	No pathogenic variants reported. SNP high associating with urofacial syndrome and that separates migraine with and without depression.	Viable, anatomically normal, and fertile.	Urinary system, facial tissue, brain.	68,174,175
GROUP III Non-essential Widely expressed	<i>EXTL2</i>	No pathogenic variants reported.	Normal embryonic development. Healthy during adult life but show altered recovery after tissue injury.		82,83
	<i>SULF1</i>	No pathogenic variants reported. SNP association with multiple sclerosis, fetus failure in IVF technique, and preeclampsia.	Non-overt phenotype, viable with no phenotypic or histological defects.		70,88,89
	<i>HPSE</i>	No pathogenic variants reported. SNP association with chronic graft-versus-host disease.	Viable, anatomically normal, and fertile.		84,86,186
GROUP IV Non-essential restricted expression	<i>EXTL1</i>	No pathogenic variants reported. SNP association with muscle lipid composition, although without pathologic impact.	Primary cultures of B-cells from mouse overexpressing <i>Extl1</i> showed altered maturation capacities.		120,190

576 Moreover, although widely distributed, *HPSE* and *SULF1* basal expressions are low (Fig. 4), possibly
577 because it is mainly required during tissue remodeling, as during wound healing, inflammation, and
578 tumor growth and metastasis¹⁵. Interestingly, this is also the case for *HPSE2* (Fig. 4), which main
579 action could also be regulatory during endogenous stimuli. Together, these reports suggest that
580 arrest of HS biosynthesis and HS chain remodeling predominantly occurs when cells and tissues are
581 submitted to instigating or adaptative conditions, and that their SNP might predispose disease.

582 3.5.4. Stimuli driven arrest of HS chain initiation or elongation

583 During biosynthesis, *EXTL1* (Group IV) and *EXTL2* (Group III) can control HS levels by respectively
584 blocking chain elongation or chain initiation when the biosynthetic machinery is overactivated, for
585 instance during wound healing, during adaptative immunological response of cells, or following other
586 internal or external stimuli¹³. No pathogenic variants have been reported for neither of these genes
587 and no genetic polymorphism has been associated with disease (Table 5). Indeed, to date, only
588 polymorphism in *EXTL1* has been associated with muscle lipid composition, although without
589 pathologic impact¹²⁰. However, *in vitro*, primary cultures of B-cells from mouse overexpressing *Extl1*
590 showed altered maturation capacities¹⁹⁰ (Table 5), suggesting that but the enzyme might be involved
591 in generation of environments or processed assuring an appropriate responsiveness to stimuli,
592 including immunological stimuli¹⁹⁰. Similarly, the *Extl2*^{-/-} mouse showed non overt phenotype,
593 although presented impaired recovery following liver and kidney injury^{82,83}. These data suggest that
594 arrest of HS chain initiation or elongation is not essential during development and homeostasis but
595 is required for appropriate response to stimuli and that SNP can predispose to altered conditions
596 with or without clinical significance.

597 4. Discussion

598 HSPGs are among the more complex molecules in biology due to their HS structural and functional
599 diversity. This diversity results from the complexity of their biosynthetic machinery coded by dozens
600 of genes, which unclear relation to each other has hidden advances in the understanding of
601 proteoglycans biology. Here, by following the PRISMA guidelines for systematic reviews and meta-
602 analysis¹⁸, we retrieved information for the 50 main human HSPG biosynthetic genes, including
603 those shared with the CSPG biosynthesis through the GAG-CP-linker tetrasaccharide, and for other
604 genes involved in Golgian homeostasis. Analysis of the documented relationship between human
605 pathogenic variants, SNPs associations with altered conditions or susceptibility to disease, null mice
606 phenotypes, gene expression profiles, and substrates specificities of enzymes coded by the
607 biosynthetic genes, resulted in the clustering in 4 Groups of genes organized depending on their
608 essentialness and expression (Fig. 5). Globally, Group I integrates ubiquitous genes which by

609 themselves can produce complete HSPG, as the group included genes coding for cores protein, all
610 the GAG-CP linker biosynthetic enzymes, and glycosyltransferases and three sulfotransferases
611 involved in the synthesis of a complete HS chain. Concerning the core proteins, Group I included
612 genes coding for all the full time pericellular HSPG core proteins (perlecan, agrin, and collagen 18)¹
613 and for 3 membrane-associated glypicans (glypicans 3, 4, and 6)¹²⁵, indicating that this group can
614 afford both essential pericellular HSPG involved structure and function of the pericellular matrix and
615 and cell membrane-associated HSPG involved in cell signaling.

616 Concerning the GAG-CP linker tetrasaccharide coding genes, analysis of their clinical variants, null
617 mice phenotypes, and substrate selectivities of their coded enzymes, resulted in a new organization
618 of the GSG-CP linker biosynthetic pathway in which the HSPG synthesis is primarily assured over
619 that of CSPG and in which the phenotypic continuum of disorders as linkeropathies and other
620 pathologies is understandable^{52,140,191}. Moreover, this new representation of the GAG-CP linker
621 biosynthetic genes supports the idea that HSPG biosynthetic enzymes can assemble into
622 'GAGosomes'^{64,192}, or 'Proteoglycanomes'¹⁹³, which consider the integration of proteoglycan core
623 proteins in the protein complexes that assure proteoglycans synthesis in the Golgi. Indeed, common
624 protein modules in the ubiquitous/essential pericellular perlecan and agrin (Group I) are different
625 from those shared by the ubiquitous/non-essential syndecans (Group III)¹, but common to those in
626 CSPGs aggrecan and neurocan, suggesting that agrin, perlecan, aggrecan, and neurocan can
627 circulate through a common HSPG/CSPG path during GAG-CP linker synthesis, as proposed in Fig.
628 6A. Moreover, aggrecan and neurocan modules are different from those carried by decorin¹,
629 supporting the splitting of the CSPG-decorin path from the HSPG/CSPG-aggrecan path under
630 interaction with XYLT1 at early steps of the GAG-CP linker biosynthesis (Fig. 6A). Likewise,
631 syndecans modules are different from those carried by agrin, perlecan, aggrecan, neurocan, and
632 decorin¹, suggesting that the tissue restricted syndecans might integrate protein complexes different
633 to those in which the ubiquitous core proteins are integrated. Thus, it will be important to investigate
634 whether the tissue restricted HS biosynthetic enzymes in Groups III and IV contain protein modules
635 that could associate them to syndecans or to other tissue restricted core proteins. Answering to this
636 question will give information on whether rHS can be carried by uCP (Fig. 6C), as syndecans, but
637 not only.

638 Concerning the HS chain, the EXTL3, EXT1, and EXT2 glycosyltransferases coding genes
639 comprehensibly clustered in Group I, which contains genes that are essential for normal
640 development and homeostasis (EXTL3, EXT1, and EXT2 are required for constructing the HSPG
641 polysaccharide). Moreover, Group I clustered the ubiquitous *NDST1*, *GLCE*, *HS2ST1*, and *HS6ST1*,
642 which appeared to be involved in the generation of uHS sequences that can then be those essential
643 for normal development and homeostasis. In the other side, the tissue restricted *NDST2-4*, *HS6ST2-*
644 *3*, and *HS3ST1-6* appeared to generate specialized rHS sequences mainly involved in
645 responsiveness to stimuli. Based in their substrate specificities^{59,159-163}, *NDST1* and *HS6ST1*, in

646 association with HS2ST and GLCE, likely form uHS NA/NS domains (Supp. Inf.), which sulfation
647 level in each position might vary depending on these ubiquitous gene expression levels in the
648 different tissues or cells⁶³⁻⁶⁵. Indeed, NDST1 generates HS domains with lower level of *N*-sulfation
649 than NDST2¹⁶⁴ while HS6ST1 shows higher selectivity for non-2-*O*-sulfated residues (hexA-GlcNS),
650 as confirmed in the *Hs6st1* null mouse⁵⁹. In the other side, mostly based in the presence of 3-*O*-
651 sulfation and higher levels of *N*- and 6-*O*-sulfations that result from NDST2 and HS6ST2 substrate
652 specificities^{12,97,100,159,161-163,177,194-199}, it appeared that specialized rHS are formed by NS
653 domains^{12,162,177}. The existence of different synthetic paths leading to NA/NS or NS domains agrees
654 the HS biosynthetic tree proposed by Yates *et al.* in which different enzymes specificities and
655 substrate abundances can determine the HS synthesis direction either through a major branch
656 assuring commonly occurring HS disaccharides or a minor branch assuring least common
657 disaccharides²⁰⁰. Separation of the two branches seems to be associated to the relative abundance
658 of two sets of structures resulting from the C5-epimerase preference to convert GlcA-GlcNS to IdoA-
659 GlcNS compared to converting GlcA-GlcNAc to IdoA-GlcNAc^{65,200}. Thus, because they are made by
660 essential biosynthetic machinery, uHS NA/NS sequences might be those that are essential for
661 normal development and homeostasis, whereas the specialized rHS sequences generated by
662 enzymes coded by Group IV genes (*NDST2*, *NDST3*, *NDST4*, *HS6ST2*, *HS6ST3*, and all *HS3STs*)
663 might be involved in specific biological functions. Accordingly, they are required for assuring
664 adaptative behaviors and/or for proper responsiveness to instigating stimuli in the tissues or cells in
665 which they are expressed.

666

667 **Ideas and Speculation**

668 This work highlighted the possible existence of uHS likely tailored by NDST1, HS6ST1 in associating
669 with HS2ST and GLCE, which together can form NA/NS domains. However, experimental evidence
670 directly demonstrating that uHS sequences in ubiquitous HSPG are formed of NA/NS require to be
671 established. Nevertheless, because of their essentialness, one can speculate that these uHS
672 sequences are those that interact and regulate HBP required for normal development and
673 homeostasis, including matrix proteins (collagen, laminin, etc.), growth factors (FGFs, VEGF, PDGF,
674 BDNF, GDNF, etc.), morphogens (Wint, hedgehog, etc.), lipid binding proteins (apolipoproteins,
675 lipoprotein lipase, etc.), cell adhesion proteins (P and L-selectin, integrins, etc.), among others^{17,165}.
676 Interestingly, several of these factors have been involved in cancer development and growth. Indeed,
677 if NA/NS sequences are those that under physiological conditions interact with these factors and
678 potentiated their activities, their excess might have over-signaling related oncogenic effects.
679 Interestingly, SULF2 is a 6-*O*-sulfatase that shows strong pro-oncogenic activity and that also
680 clustered in Group I. Thus, by de-sulfating NS sequences, SULF2 can generate biologically active
681 NA/NS-like sequences that potentiate growth factors activities. If this is the case SULF2 will be pro-
682 oncogenic, as is the case¹⁴. Although compensation phenomena among SULF1 and SULF2 can be

683 argued, it noteworthy that while SULF2 is a pro-oncogene, SULF1 shows anti-oncogenic activity¹⁴,
684 suggesting differential functions. Accordingly, SULF1 might inactivate excess of NA/NS sequences
685 by de-sulfating uHS and thus generating under-sulfated 6-O-desulfated NA/NS domains unable to
686 promote HBP trophic effects^{14,62}. Thus, it is possible that by generating biologically active NA/NS-
687 like sequences, SULF2 favors growth factors activities acting as pro-oncogene, whereas SULF1
688 participate to inactivation of active NA/NS sequences by generating under sulfated and inactive
689 NA/NS domains, acting as anti-oncogene. This hypothesis requires large research to be confirmed
690 or discarded. Similarly, based in information from the knockout mice and GWAS data, it appeared
691 that specialized rHS sequences are those required for appropriate responsiveness to stimuli and
692 adaptive behaviors in tissues in which each gene is specifically expressed. An additional question of
693 interest is whether these specialized rHS are those that afford to HS chains their fine structural
694 specificity, which will then not be directly related to fundamental processes in life, but mostly to
695 specific tissue responsiveness to stimuli, resistance or vulnerability to disease or altered behaviors,
696 as those observed in complex neurological disorders. Moreover, it is possible that rHS sequences
697 (their biosynthetic genes knockout mice lives healthy) are carried by Group II and III core proteins
698 (their biosynthetic genes knockout mice lives healthy), whereas uHS sequences (their biosynthetic
699 genes knockout mice die) are carried by the ubiquitous core proteins (their biosynthetic genes
700 knockout mice die). Answering to these questions will facilitate research aiming to understand the
701 differential role of HSPG core proteins and the HS chains that they carry in a large variety of
702 biological and pathological context. Thus, although to date it is not yet possible to sequence single
703 HS chains isolated from their physiological contexts, the selective purification of core proteins from
704 tissues or cells will make available their specific HS chains, in which the research of NA/NS or NS
705 sequences could be performed. Finally, as HS chains are long, one should consider that the
706 specialized rHS sequences might be those that gives to cells the capacity to generate specific HS
707 interactomes with cell membrane proteins, or matrix proteins. The involvement of Group IV rHS
708 biosynthetic genes in complex pathologies, as neurologic or behavioral disorders, might represent a
709 solution for the identification of pathologies associating specific rHS interactomes. We are currently
710 working in this direction.

711 **In conclusion**, by analyzing clinical variants and transcriptomic databases and literature records for
712 biochemical and functional information on HSPG biosynthetic machinery genes, we decrypted
713 essential features of proteoglycans and HS structural and functional diversity. Our analysis considers
714 new concepts non developed in previous works, for instance those in which HS structures are
715 defined by the HSPG biosynthetic genes expression levels⁶³⁻⁶⁵. From this analysis, we propose a
716 clinical-variant and substrate selectivity-based proteoglycan biosynthetic pathway in which HSPG
717 are primarily assured over CSPG, and in which the HS chains or sequences are characterized for
718 carrying either an ubiquitous 'sulfation level specificity' (uHS) or a specialized 'sulfation pattern

719 specificity' (rHS), depending on the tissue in where they are made. This work opens new routes of
720 research for a better understanding of the roles of HSPG in physiology and pathology.

721 **5. Acknowledgments**

722 This work has received funding from the ANR SkelGAG and from the European Union's Horizon
723 2020 Research and Innovation Program (grant agreement No 737390). G. Barreto was funded by
724 the "Centre National de la Recherche Scientifique" (CNRS, France), "Délégation Centre-Est" (CNRS-
725 DR6), the "Lorraine Université" (LU, France) through the initiative "Lorraine Université d'Excellence"
726 and the dispositive "Future Leader" and the "Deutsche Forschungsgemeinschaft" (DFG, Bonn,
727 Germany) (BA 4036/4-1). We thank ArrestAD partners, particularly Prof. T. van Kuppevelt (Radboud
728 University, the Netherlands) and Prof. D. Fernig (University of Liverpool, UK), to Prof. P. Albanese,
729 Dr. A. Fifre (University Paris Est Créteil, France), Prof. J-P. Li, Prof. U. Lindahl, and Prof. L. Kjellen
730 (Uppsala University, Sweden), for interesting discussions.

731 **6. Competing interests**

732 The authors declare that they have no competing interests.

733 **7. Author contributions**

734 DPG designed the study and wrote the manuscript. DPG, MOO, BDSF, and JDR analyzed the data.
735 DPG, GB, BDSF, and MMO participated to data organization. DPG, MOO, GB, NR, and AM
736 participated to figures design. SC, MBH, XL, GLD, and OGV participated to data analysis and
737 literature review. All authors discussed results and commented the manuscript for improvement.

738 **References**

- 739 1 Iozzo, R. V. & Schaefer, L. Proteoglycan form and function: A comprehensive nomenclature of
740 proteoglycans. *Matrix Biol* **42**, 11-55, doi:10.1016/j.matbio.2015.02.003 (2015).
- 741 2 Li, J. P. & Kusche-Gullberg, M. Heparan Sulfate: Biosynthesis, Structure, and Function. *International*
742 *review of cell and molecular biology* **325**, 215-273, doi:10.1016/bs.ircmb.2016.02.009 (2016).
- 743 3 Sarrazin, S., Lamanna, W. C. & Esko, J. D. Heparan sulfate proteoglycans. *Cold Spring Harbor*
744 *perspectives in biology* **3**, doi:10.1101/cshperspect.a004952 (2011).
- 745 4 Gao, J. & Huang, X. Recent advances on glycosyltransferases involved in the biosynthesis of the
746 proteoglycan linkage region. *Advances in carbohydrate chemistry and biochemistry* **80**, 95-119,
747 doi:10.1016/bs.accb.2021.10.003 (2021).
- 748 5 Sasarman, F. *et al.* Biosynthesis of glycosaminoglycans: associated disorders and biochemical tests.
749 *Journal of inherited metabolic disease* **39**, 173-188, doi:10.1007/s10545-015-9903-z (2016).

- 750 6 Wen, J. *et al.* Xylose phosphorylation functions as a molecular switch to regulate proteoglycan
751 biosynthesis. *Proceedings of the National Academy of Sciences of the United States of America* **111**,
752 15723-15728, doi:10.1073/pnas.1417993111 (2014).
- 753 7 Koike, T., Izumikawa, T., Sato, B. & Kitagawa, H. Identification of phosphatase that dephosphorylates
754 xylose in the glycosaminoglycan-protein linkage region of proteoglycans. *The Journal of biological*
755 *chemistry* **289**, 6695-6708, doi:10.1074/jbc.M113.520536 (2014).
- 756 8 Paganini, C. *et al.* Calcium activated nucleotidase 1 (CANT1) is critical for glycosaminoglycan
757 biosynthesis in cartilage and endochondral ossification. *Matrix Biol* **81**, 70-90,
758 doi:10.1016/j.matbio.2018.11.002 (2019).
- 759 9 Paganini, C., Gramegna Tota, C., Superti-Furga, A. & Rossi, A. Skeletal Dysplasias Caused by
760 Sulfation Defects. *International journal of molecular sciences* **21**, doi:10.3390/ijms21082710 (2020).
- 761 10 Dubail, J. *et al.* SLC10A7 mutations cause a skeletal dysplasia with amelogenesis imperfecta
762 mediated by GAG biosynthesis defects. *Nature communications* **9**, 3087, doi:10.1038/s41467-018-
763 05191-8 (2018).
- 764 11 Li, J. P. Glucuronyl C5-epimerase an enzyme converting glucuronic acid to iduronic acid in heparan
765 sulfate/heparin biosynthesis. *Progress in molecular biology and translational science* **93**, 59-78,
766 doi:10.1016/s1877-1173(10)93004-4 (2010).
- 767 12 Thacker, B. E., Xu, D., Lawrence, R. & Esko, J. D. Heparan sulfate 3-O-sulfation: a rare modification
768 in search of a function. *Matrix Biol* **35**, 60-72, doi:10.1016/j.matbio.2013.12.001 (2014).
- 769 13 Busse-Wicher, M., Wicher, K. B. & Kusche-Gullberg, M. The exostosin family: proteins with many
770 functions. *Matrix Biol* **35**, 25-33, doi:10.1016/j.matbio.2013.10.001 (2014).
- 771 14 El Masri, R., Seffouh, A., Lortat-Jacob, H. & Vives, R. R. The "in and out" of glucosamine 6-O-sulfation:
772 the 6th sense of heparan sulfate. *Glycoconjugate journal* **34**, 285-298, doi:10.1007/s10719-016-9736-
773 5 (2017).
- 774 15 Masola, V., Bellin, G., Gambaro, G. & Onisto, M. Heparanase: A Multitasking Protein Involved in
775 Extracellular Matrix (ECM) Remodeling and Intracellular Events. *Cells* **7**, doi:10.3390/cells7120236
776 (2018).
- 777 16 Mayfosh, A. J., Nguyen, T. K. & Hulett, M. D. The Heparanase Regulatory Network in Health and
778 Disease. *International journal of molecular sciences* **22**, doi:10.3390/ijms222011096 (2021).
- 779 17 Xie, M. & Li, J. P. Heparan sulfate proteoglycan - A common receptor for diverse cytokines. *Cell Signal*
780 **54**, 115-121, doi:10.1016/j.cellsig.2018.11.022 (2019).
- 781 18 Page, M. J. *et al.* The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.
782 *Rev Esp Cardiol (Engl Ed)* **74**, 790-799, doi:10.1016/j.rec.2021.07.010 (2021).
- 783 19 Papatheodorou, I. *et al.* Expression Atlas: gene and protein expression across multiple studies and
784 organisms. *Nucleic Acids Res* **46**, D246-D251, doi:10.1093/nar/gkx1158 (2018).
- 785 20 Filippi, L. & Braat, A. J. Theragnostics in primary and secondary liver tumors: the need for a
786 personalized approach. *The quarterly journal of nuclear medicine and molecular imaging : official*
787 *publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of*
788 *Radiopharmacology (IAR), [and] Section of the So* **65**, 353-370, doi:10.23736/s1824-4785.21.03407-
789 5 (2021).
- 790 21 Marques, C., Reis, C. A., Vivès, R. R. & Magalhães, A. Heparan Sulfate Biosynthesis and Sulfation
791 Profiles as Modulators of Cancer Signalling and Progression. *Frontiers in oncology* **11**, 778752,
792 doi:10.3389/fonc.2021.778752 (2021).
- 793 22 Arikawa-Hirasawa, E., Watanabe, H., Takami, H., Hassell, J. R. & Yamada, Y. Perlecan is essential
794 for cartilage and cephalic development. *Nature genetics* **23**, 354-358, doi:10.1038/15537 (1999).
- 795 23 Gubbiotti, M. A., Neill, T. & Iozzo, R. V. A current view of perlecan in physiology and pathology: A
796 mosaic of functions. *Matrix Biol* **57-58**, 285-298, doi:10.1016/j.matbio.2016.09.003 (2017).
- 797 24 Liu, H. & Huang, W. The Association between Genes Polymorphisms of Heparan Sulfate Proteoglycan
798 2 (HSPG2) and Chondroitin Sulfate Proteoglycan 2 (CSPG2) and Intracranial Aneurysm Susceptibility:
799 A Meta-Analysis. *Iranian journal of public health* **48**, 1945-1951 (2019).
- 800 25 Martinez, J. R., Dhawan, A. & Farach-Carson, M. C. Modular Proteoglycan Perlecan/HSPG2:
801 Mutations, Phenotypes, and Functions. *Genes* **9**, doi:10.3390/genes9110556 (2018).
- 802 26 Daniels, M. P. The role of agrin in synaptic development, plasticity and signaling in the central nervous
803 system. *Neurochemistry international* **61**, 848-853, doi:10.1016/j.neuint.2012.02.028 (2012).
- 804 27 Gautam, M. *et al.* Defective neuromuscular synaptogenesis in agrin-deficient mutant mice. *Cell* **85**,
805 525-535, doi:10.1016/s0092-8674(00)81253-2 (1996).

- 806 28 Hausser, H. J., Ruegg, M. A., Brenner, R. E. & Ksiazek, I. Agrin is highly expressed by chondrocytes
807 and is required for normal growth. *Histochemistry and cell biology* **127**, 363-374, doi:10.1007/s00418-
808 006-0258-2 (2007).
- 809 29 Nicole, S. *et al.* Agrin mutations lead to a congenital myasthenic syndrome with distal muscle
810 weakness and atrophy. *Brain : a journal of neurology* **137**, 2429-2443, doi:10.1093/brain/awu160
811 (2014).
- 812 30 Fukai, N. *et al.* Lack of collagen XVIII/endostatin results in eye abnormalities. *The EMBO journal* **21**,
813 1535-1544, doi:10.1093/emboj/21.7.1535 (2002).
- 814 31 Heljasvaara, R., Aikio, M., Ruotsalainen, H. & Pihlajaniemi, T. Collagen XVIII in tissue homeostasis
815 and dysregulation - Lessons learned from model organisms and human patients. *Matrix Biol* **57-58**,
816 55-75, doi:10.1016/j.matbio.2016.10.002 (2017).
- 817 32 Seppinen, L. & Pihlajaniemi, T. The multiple functions of collagen XVIII in development and disease.
818 *Matrix Biol* **30**, 83-92, doi:10.1016/j.matbio.2010.11.001 (2011).
- 819 33 Cano-Gauci, D. F. *et al.* Glypican-3-deficient mice exhibit developmental overgrowth and some of the
820 abnormalities typical of Simpson-Golabi-Behmel syndrome. *The Journal of cell biology* **146**, 255-264,
821 doi:10.1083/jcb.146.1.255 (1999).
- 822 34 Cottureau, E. *et al.* Phenotypic spectrum of Simpson-Golabi-Behmel syndrome in a series of 42 cases
823 with a mutation in GPC3 and review of the literature. *American journal of medical genetics. Part C,*
824 *Seminars in medical genetics* **163c**, 92-105, doi:10.1002/ajmg.c.31360 (2013).
- 825 35 Iglesias, B. V. *et al.* Expression pattern of glypican-3 (GPC3) during human embryonic and fetal
826 development. *Histology and histopathology* **23**, 1333-1340, doi:10.14670/hh-23.1333 (2008).
- 827 36 Amor, D. J. *et al.* Pathogenic Variants in GPC4 Cause Keipert Syndrome. *American journal of human*
828 *genetics* **104**, 914-924, doi:10.1016/j.ajhg.2019.02.026 (2019).
- 829 37 Dowling, C. & Allen, N. J. Mice Lacking Glypican 4 Display Juvenile Hyperactivity and Adult Social
830 Interaction Deficits. *Brain plasticity (Amsterdam, Netherlands)* **4**, 197-209, doi:10.3233/bpl-180079
831 (2018).
- 832 38 Campos-Xavier, A. B. *et al.* Mutations in the heparan-sulfate proteoglycan glypican 6 (GPC6) impair
833 endochondral ossification and cause recessive omdysplasia. *American journal of human genetics*
834 **84**, 760-770, doi:10.1016/j.ajhg.2009.05.002 (2009).
- 835 39 Capurro, M. *et al.* Glypican-6 promotes the growth of developing long bones by stimulating Hedgehog
836 signaling. *The Journal of cell biology* **216**, 2911-2926, doi:10.1083/jcb.201605119 (2017).
- 837 40 Kemp, J. P. *et al.* Identification of 153 new loci associated with heel bone mineral density and functional
838 involvement of GPC6 in osteoporosis. *Nature genetics* **49**, 1468-1475, doi:10.1038/ng.3949 (2017).
- 839 41 Bui, C. *et al.* XYLT1 mutations in Desbuquois dysplasia type 2. *American journal of human genetics*
840 **94**, 405-414, doi:10.1016/j.ajhg.2014.01.020 (2014).
- 841 42 Mis, E. K. *et al.* Forward genetics defines Xylt1 as a key, conserved regulator of early chondrocyte
842 maturation and skeletal length. *Developmental biology* **385**, 67-82, doi:10.1016/j.ydbio.2013.10.014
843 (2014).
- 844 43 Taylan, F. *et al.* Spondyloocular Syndrome: Novel Mutations in XYLT2 Gene and Expansion of the
845 Phenotypic Spectrum. *Journal of bone and mineral research : the official journal of the American*
846 *Society for Bone and Mineral Research* **31**, 1577-1585, doi:10.1002/jbmr.2834 (2016).
- 847 44 Caraffi, S. G. *et al.* Severe Peripheral Joint Laxity is a Distinctive Clinical Feature of
848 Spondylodysplastic-Ehlers-Danlos Syndrome (EDS)-B4GALT7 and Spondylodysplastic-EDS-
849 B3GALT6. *Genes* **10**, doi:10.3390/genes10100799 (2019).
- 850 45 Mihalic Mosher, T. *et al.* Expansion of B4GALT7 linkeropathy phenotype to include perinatal lethal
851 skeletal dysplasia. *European journal of human genetics : EJHG*, doi:10.1038/s41431-019-0464-8
852 (2019).
- 853 46 Malfait, F. *et al.* Defective initiation of glycosaminoglycan synthesis due to B3GALT6 mutations causes
854 a pleiotropic Ehlers-Danlos-syndrome-like connective tissue disorder. *American journal of human*
855 *genetics* **92**, 935-945, doi:10.1016/j.ajhg.2013.04.016 (2013).
- 856 47 Van Damme, T. *et al.* Biallelic B3GALT6 mutations cause spondylodysplastic Ehlers-Danlos
857 syndrome. *Human molecular genetics* **27**, 3475-3487, doi:10.1093/hmg/ddy234 (2018).
- 858 48 Ritelli, M. *et al.* Further Defining the Phenotypic Spectrum of B3GAT3 Mutations and Literature Review
859 on Linkeropathy Syndromes. *Genes* **10**, doi:10.3390/genes10090631 (2019).

- 860 49 Kuroda, Y. *et al.* A novel gene (FAM20B encoding glycosaminoglycan xylosylkinase) for neonatal short
861 limb dysplasia resembling Desbuquois dysplasia. *Clinical genetics* **95**, 713-717,
862 doi:10.1111/cge.13530 (2019).
- 863 50 Spyroglou, A. *et al.* Diastrophic dysplasia sulfate transporter (SLC26A2) is expressed in the adrenal
864 cortex and regulates aldosterone secretion. *Hypertension (Dallas, Tex. : 1979)* **63**, 1102-1109,
865 doi:10.1161/hypertensionaha.113.02504 (2014).
- 866 51 Asselta, R. *et al.* X Chromosome Contribution to the Genetic Architecture of Primary Biliary
867 Cholangitis. *Gastroenterology* **160**, 2483-2495.e2426, doi:10.1053/j.gastro.2021.02.061 (2021).
- 868 52 Taylan, F. & Mäkitie, O. Abnormal Proteoglycan Synthesis Due to Gene Defects Causes Skeletal
869 Diseases with Overlapping Phenotypes. *Hormone and metabolic research = Hormon- und*
870 *Stoffwechselforschung = Hormones et métabolisme* **48**, 745-754, doi:10.1055/s-0042-118706 (2016).
- 871 53 Osman, N. M., Kagohashi, Y., Udagawa, J. & Otani, H. Alpha1,4-N-acetylglucosaminyltransferase
872 encoding gene EXTL3 expression pattern in mouse adult and developing tissues with special attention
873 to the pancreas. *Anatomy and embryology* **207**, 333-341, doi:10.1007/s00429-003-0348-z (2003).
- 874 54 Yamada, S. Specific functions of Exostosin-like 3 (EXTL3) gene products. *Cellular & molecular biology*
875 *letters* **25**, 39, doi:10.1186/s11658-020-00231-y (2020).
- 876 55 Lin, X. *et al.* Disruption of gastrulation and heparan sulfate biosynthesis in EXT1-deficient mice.
877 *Developmental biology* **224**, 299-311, doi:10.1006/dbio.2000.9798 (2000).
- 878 56 Stickens, D., Zak, B. M., Rougier, N., Esko, J. D. & Werb, Z. Mice deficient in Ext2 lack heparan sulfate
879 and develop exostoses. *Development (Cambridge, England)* **132**, 5055-5068, doi:10.1242/dev.02088
880 (2005).
- 881 57 Li, J. P. *et al.* Targeted disruption of a murine glucuronyl C5-epimerase gene results in heparan sulfate
882 lacking L-iduronic acid and in neonatal lethality. *The Journal of biological chemistry* **278**, 28363-28366,
883 doi:10.1074/jbc.C300219200 (2003).
- 884 58 Armstrong, L. *et al.* A girl with developmental delay, ataxia, cranial nerve palsies, severe respiratory
885 problems in infancy-Expanding NDST1 syndrome. *American journal of medical genetics. Part A* **173**,
886 712-715, doi:10.1002/ajmg.a.37621 (2017).
- 887 59 Habuchi, H. *et al.* Mice deficient in heparan sulfate 6-O-sulfotransferase-1 exhibit defective heparan
888 sulfate biosynthesis, abnormal placentation, and late embryonic lethality. *The Journal of biological*
889 *chemistry* **282**, 15578-15588, doi:10.1074/jbc.M607434200 (2007).
- 890 60 Merry, C. L. *et al.* The molecular phenotype of heparan sulfate in the Hs2st^{-/-} mutant mouse. *The*
891 *Journal of biological chemistry* **276**, 35429-35434, doi:10.1074/jbc.M100379200 (2001).
- 892 61 Ringvall, M. & Kjellen, L. Mice deficient in heparan sulfate N-deacetylase/N-sulfotransferase 1.
893 *Progress in molecular biology and translational science* **93**, 35-58, doi:10.1016/s1877-1173(10)93003-
894 2 (2010).
- 895 62 Chiu, L. T. *et al.* Trisaccharide Sulfate and Its Sulfonamide as an Effective Substrate and Inhibitor of
896 Human Endo-O-sulfatase-1. *Journal of the American Chemical Society* **142**, 5282-5292,
897 doi:10.1021/jacs.0c00005 (2020).
- 898 63 Lindahl, U. & Kjellen, L. Pathophysiology of heparan sulphate: many diseases, few drugs. *J Intern Med*
899 **273**, 555-571, doi:10.1111/joim.12061 (2013).
- 900 64 Kreuger, J. & Kjellén, L. Heparan sulfate biosynthesis: regulation and variability. *The journal of*
901 *histochemistry and cytochemistry : official journal of the Histochemistry Society* **60**, 898-907,
902 doi:10.1369/0022155412464972 (2012).
- 903 65 Huang, Y. F., Mizumoto, S. & Fujita, M. Novel Insight Into Glycosaminoglycan Biosynthesis Based on
904 Gene Expression Profiles. *Frontiers in cell and developmental biology* **9**, 709018,
905 doi:10.3389/fcell.2021.709018 (2021).
- 906 66 Grobe, K. & Esko, J. D. Regulated translation of heparan sulfate N-acetylglucosamine N-
907 deacetylase/n-sulfotransferase isozymes by structured 5'-untranslated regions and internal ribosome
908 entry sites. *The Journal of biological chemistry* **277**, 30699-30706 (2002).
- 909 67 Pinhal, M. A. S., Melo, C. M. & Nader, H. B. The Good and Bad Sides of Heparanase-1 and
910 Heparanase-2. *Advances in experimental medicine and biology* **1221**, 821-845, doi:10.1007/978-3-
911 030-34521-1_36 (2020).
- 912 68 Petschner, P. *et al.* A replication study separates polymorphisms behind migraine with and without
913 depression. *PLoS one* **16**, e0261477, doi:10.1371/journal.pone.0261477 (2021).
- 914 69 Nemoto, T. *et al.* Endothelial glycocalyx and severity and vulnerability of coronary plaque in patients
915 with coronary artery disease. *Atherosclerosis* **302**, 1-7, doi:10.1016/j.atherosclerosis.2020.04.014
916 (2020).

- 917 70 Okolicsanyi, R. K., Bluhm, J., Miller, C., Griffiths, L. R. & Haupt, L. M. An investigation of genetic
918 polymorphisms in heparan sulfate proteoglycan core proteins and key modification enzymes in an
919 Australian Caucasian multiple sclerosis population. *Human genomics* **14**, 18, doi:10.1186/s40246-
920 020-00264-6 (2020).
- 921 71 Saboia, Z., Meneses, G. C., Martins, A. M. C., Daher, E. F. & Silva Junior, G. B. Association between
922 syndecan-1 and renal function in adolescents with excess weight: evidence of subclinical kidney
923 disease and endothelial dysfunction. *Brazilian journal of medical and biological research = Revista*
924 *brasileira de pesquisas medicas e biologicas* **51**, e7174, doi:10.1590/1414-431x20177174 (2018).
- 925 72 Ashley-Koch, A. E. *et al.* Genome-wide association study of posttraumatic stress disorder in a cohort
926 of Iraq-Afghanistan era veterans. *Journal of affective disorders* **184**, 225-234,
927 doi:10.1016/j.jad.2015.03.049 (2015).
- 928 73 Chang, B. C., Hwang, L. C. & Huang, W. H. Positive Association of Metabolic Syndrome with a Single
929 Nucleotide Polymorphism of Syndecan-3 (rs2282440) in the Taiwanese Population. *International*
930 *journal of endocrinology* **2018**, 9282598, doi:10.1155/2018/9282598 (2018).
- 931 74 Ha, E. *et al.* Positive association of obesity with single nucleotide polymorphisms of syndecan 3 in the
932 Korean population. *The Journal of clinical endocrinology and metabolism* **91**, 5095-5099,
933 doi:10.1210/jc.2005-2086 (2006).
- 934 75 Moons, T. *et al.* Clock genes and body composition in patients with schizophrenia under treatment
935 with antipsychotic drugs. *Schizophrenia research* **125**, 187-193, doi:10.1016/j.schres.2010.10.008
936 (2011).
- 937 76 Schüring, A. N. *et al.* Role of syndecan-3 polymorphisms in obesity and female hyperandrogenism.
938 *Journal of molecular medicine (Berlin, Germany)* **87**, 1241-1250, doi:10.1007/s00109-009-0529-1
939 (2009).
- 940 77 De Luca, M. *et al.* A conserved role for syndecan family members in the regulation of whole-body
941 energy metabolism. *PloS one* **5**, e11286, doi:10.1371/journal.pone.0011286 (2010).
- 942 78 Nagy, N. *et al.* The altered expression of syndecan 4 in the uninvolved skin of venous leg ulcer patients
943 may predispose to venous leg ulcer. *Wound repair and regeneration : official publication of the Wound*
944 *Healing Society [and] the European Tissue Repair Society* **16**, 495-502, doi:10.1111/j.1524-
945 475X.2008.00394.x (2008).
- 946 79 Rose, G. *et al.* Metabolism and successful aging: Polymorphic variation of syndecan-4 (SDC4) gene
947 associate with longevity and lipid profile in healthy elderly Italian subjects. *Mechanisms of ageing and*
948 *development* **150**, 27-33, doi:10.1016/j.mad.2015.08.003 (2015).
- 949 80 Bai, M. R. *et al.* Association of common variation in ADD3 and GPC1 with biliary atresia susceptibility.
950 *Aging* **12**, 7163-7182, doi:10.18632/aging.103067 (2020).
- 951 81 Potkin, S. G. *et al.* A genome-wide association study of schizophrenia using brain activation as a
952 quantitative phenotype. *Schizophrenia bulletin* **35**, 96-108, doi:10.1093/schbul/sbn155 (2009).
- 953 82 Nadanaka, S., Kagiya, S. & Kitagawa, H. Roles of EXTL2, a member of the EXT family of tumour
954 suppressors, in liver injury and regeneration processes. *The Biochemical journal* **454**, 133-145,
955 doi:10.1042/bj20130323 (2013).
- 956 83 Purnomo, E. *et al.* Glycosaminoglycan overproduction in the aorta increases aortic calcification in
957 murine chronic kidney disease. *Journal of the American Heart Association* **2**, e000405,
958 doi:10.1161/jaha.113.000405 (2013).
- 959 84 Martin, P. J. *et al.* Replication of associations between genetic polymorphisms and chronic graft-
960 versus-host disease. *Blood* **128**, 2450-2456, doi:10.1182/blood-2016-07-728063 (2016).
- 961 85 Ostrovsky, O. *et al.* The HPSE Gene Insulator-A Novel Regulatory Element That Affects Heparanase
962 Expression, Stem Cell Mobilization, and the Risk of Acute Graft versus Host Disease. *Cells* **10**,
963 doi:10.3390/cells10102523 (2021).
- 964 86 Ostrovsky, O., Shimoni, A., Rand, A., Vlodavsky, I. & Nagler, A. Genetic variations in the heparanase
965 gene (HPSE) associate with increased risk of GVHD following allogeneic stem cell transplantation:
966 effect of discrepancy between recipients and donors. *Blood* **115**, 2319-2328, doi:10.1182/blood-2009-
967 08-236455 (2010).
- 968 87 Oshima, K. *et al.* Loss of endothelial sulfatase-1 after experimental sepsis attenuates subsequent
969 pulmonary inflammatory responses. *American journal of physiology. Lung cellular and molecular*
970 *physiology* **317**, L667-L677, doi:10.1152/ajplung.00175.2019 (2019).
- 971 88 Taghizadeh, E. *et al.* SULF 1 gene polymorphism, rs6990375 is in significant association with fetus
972 failure in IVF technique. *Iranian journal of reproductive medicine* **13**, 215-220 (2015).

- 973 89 Zhang, P. *et al.* Polymorphisms in Sex Hormone Metabolism Genes and Risk of Preeclampsia in
974 Taiyuan, China. *Gynecologic and obstetric investigation* **83**, 179-186, doi:10.1159/000478931 (2018).
- 975 90 Kamimura, K. & Maeda, N. Glypicans and Heparan Sulfate in Synaptic Development, Neural Plasticity,
976 and Neurological Disorders. *Front Neural Circuits* **15**, 595596, doi:10.3389/fncir.2021.595596 (2021).
- 977 91 Lugert, S. *et al.* Glypican-2 levels in cerebrospinal fluid predict the status of adult hippocampal
978 neurogenesis. *Scientific reports* **7**, 46543, doi:10.1038/srep46543 (2017).
- 979 92 Luxardi, G. *et al.* Glypicans are differentially expressed during patterning and neurogenesis of early
980 mouse brain. *Biochem Biophys Res Commun* **352**, 55-60, doi:10.1016/j.bbrc.2006.10.185 (2007).
- 981 93 Choraży, M. *et al.* Analysis of chosen SNVs in GPC5, CD58 and IRF8 genes in multiple sclerosis
982 patients. *Advances in medical sciences* **64**, 230-234, doi:10.1016/j.advms.2018.12.004 (2019).
- 983 94 Guan, Y. *et al.* The Role of Cell Growth-Related Gene Copy Number Variation in Autoimmune Thyroid
984 Disease. *Biological trace element research* **195**, 409-416, doi:10.1007/s12011-019-01880-7 (2020).
- 985 95 Okamoto, K. *et al.* Common variation in GPC5 is associated with acquired nephrotic syndrome. *Nature*
986 *genetics* **43**, 459-463, doi:10.1038/ng.792 (2011).
- 987 96 Bush, K. T. *et al.* N-sulfation of heparan sulfate regulates early branching events in the developing
988 mammary gland. *The Journal of biological chemistry* **287**, 42064-42070,
989 doi:10.1074/jbc.M112.423327 (2012).
- 990 97 Ledin, J. *et al.* Enzymatically active N-deacetylase/N-sulfotransferase-2 is present in liver but does not
991 contribute to heparan sulfate N-sulfation. *The Journal of biological chemistry* **281**, 35727-35734,
992 doi:10.1074/jbc.M604113200 (2006).
- 993 98 Ledin, J. *et al.* Heparan sulfate structure in mice with genetically modified heparan sulfate production.
994 *The Journal of biological chemistry* **279**, 42732-42741, doi:10.1074/jbc.M405382200 (2004).
- 995 99 Lencz, T. *et al.* Genome-wide association study implicates NDST3 in schizophrenia and bipolar
996 disorder. *Nature communications* **4**, 2739, doi:10.1038/ncomms3739 (2013).
- 997 100 Pallerla, S. R. *et al.* Altered heparan sulfate structure in mice with deleted NDST3 gene function. *The*
998 *Journal of biological chemistry* **283**, 16885-16894, doi:10.1074/jbc.M709774200 (2008).
- 999 101 Wang, L. *et al.* Association study of NDST3 gene for schizophrenia, bipolar disorder, major depressive
1000 disorder in the Han Chinese population. *American journal of medical genetics. Part B,*
1001 *Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics*
1002 **177**, 3-9, doi:10.1002/ajmg.b.32573 (2018).
- 1003 102 Eicher, J. D. *et al.* Genome-wide association study of shared components of reading disability and
1004 language impairment. *Genes, brain, and behavior* **12**, 792-801, doi:10.1111/gbb.12085 (2013).
- 1005 103 Jao, T. M. *et al.* Alteration of colonic epithelial cell differentiation in mice deficient for glucosaminyl N-
1006 deacetylase/N-sulfotransferase 4. *Oncotarget* **7**, 84938-84950, doi:10.18632/oncotarget.12915
1007 (2016).
- 1008 104 Guo, Y. *et al.* Downregulation of HS6ST2 by miR-23b-3p enhances matrix degradation through p38
1009 MAPK pathway in osteoarthritis. *Cell death & disease* **9**, 699, doi:10.1038/s41419-018-0729-0 (2018).
- 1010 105 Paganini, L. *et al.* A HS6ST2 gene variant associated with X-linked intellectual disability and severe
1011 myopia in two male twins. *Clinical genetics* **95**, 368-374, doi:10.1111/cge.13485 (2019).
- 1012 106 Iwase, M. *et al.* Differential Effect of Polymorphisms on Body Mass Index Across the Life Course of
1013 Japanese: The Japan Multi-Institutional Collaborative Cohort Study. *Journal of epidemiology* **31**, 172-
1014 179, doi:10.2188/jea.JE20190296 (2021).
- 1015 107 Wang, K. S., Wang, L., Liu, X. & Zeng, M. Association of HS6ST3 gene polymorphisms with obesity
1016 and triglycerides: gene x gender interaction. *Journal of genetics* **92**, 395-402 (2013).
- 1017 108 Desikan, R. S. *et al.* Polygenic Overlap Between C-Reactive Protein, Plasma Lipids, and Alzheimer
1018 Disease. *Circulation* **131**, 2061-2069, doi:10.1161/circulationaha.115.015489 (2015).
- 1019 109 Shworak, N. W., HajMohammadi, S., de Agostini, A. I. & Rosenberg, R. D. Mice deficient in heparan
1020 sulfate 3-O-sulfotransferase-1: normal hemostasis with unexpected perinatal phenotypes.
1021 *Glycoconjugate journal* **19**, 355-361, doi:10.1023/a:1025377206600 (2002).
- 1022 110 Witoelar, A. *et al.* Meta-analysis of Alzheimer's disease on 9,751 samples from Norway and IGAP
1023 study identifies four risk loci. *Scientific reports* **8**, 18088, doi:10.1038/s41598-018-36429-6 (2018).
- 1024 111 Azuara, D. *et al.* Novel methylation panel for the early detection of neoplasia in high-risk ulcerative
1025 colitis and Crohn's colitis patients. *Inflammatory bowel diseases* **19**, 165-173, doi:10.1002/ibd.22994
1026 (2013).

- 1027 112 Yu, H., Guo, W., Liu, Y. & Wang, Y. Immune Characteristics Analysis and Transcriptional Regulation
1028 Prediction Based on Gene Signatures of Chronic Obstructive Pulmonary Disease. *International journal*
1029 *of chronic obstructive pulmonary disease* **16**, 3027-3039, doi:10.2147/copd.s325328 (2021).
- 1030 113 Amraoui, F. *et al.* Placental expression of heparan sulfate 3-O-sulfotransferase-3A1 in normotensive
1031 and pre-eclamptic pregnancies. *Placenta* **36**, 1218-1224, doi:10.1016/j.placenta.2015.09.008 (2015).
- 1032 114 Huang, J. *et al.* Identification of gene and microRNA changes in response to smoking in human airway
1033 epithelium by bioinformatics analyses. *Medicine* **98**, e17267, doi:10.1097/md.00000000000017267
1034 (2019).
- 1035 115 Joubert, B. R., Franceschini, N., Mwapasa, V., North, K. E. & Meshnick, S. R. Regulation of CCR5
1036 expression in human placenta: insights from a study of mother-to-child transmission of HIV in Malawi.
1037 *PloS one* **5**, e9212, doi:10.1371/journal.pone.0009212 (2010).
- 1038 116 Spencer, K. L. *et al.* Dissection of chromosome 16p12 linkage peak suggests a possible role for
1039 CACNG3 variants in age-related macular degeneration susceptibility. *Investigative ophthalmology &*
1040 *visual science* **52**, 1748-1754, doi:10.1167/iovs.09-5112 (2011).
- 1041 117 Wang, Q. *et al.* Genome-wide association analysis with gray matter volume as a quantitative
1042 phenotype in first-episode treatment-naive patients with schizophrenia. *PloS one* **8**, e75083,
1043 doi:10.1371/journal.pone.0075083 (2013).
- 1044 118 Bork, K. *et al.* Novel hereditary angioedema linked with a heparan sulfate 3-O-sulfotransferase 6 gene
1045 mutation. *J Allergy Clin Immunol*, doi:10.1016/j.jaci.2021.01.011 (2021).
- 1046 119 Santacroce, R., D'Andrea, G., Maffione, A. B., Margaglione, M. & d'Apolito, M. The Genetics of
1047 Hereditary Angioedema: A Review. *Journal of clinical medicine* **10**, doi:10.3390/jcm10092023 (2021).
- 1048 120 Jiang, Z., Michal, J. J., Wu, X. L., Pan, Z. & MacNeil, M. D. The heparan and heparin metabolism
1049 pathway is involved in regulation of fatty acid composition. *International journal of biological sciences*
1050 **7**, 659-663, doi:10.7150/ijbs.7.659 (2011).
- 1051 121 Pastor-Pareja, J. C. Atypical basement membranes and basement membrane diversity - what is
1052 normal anyway? *Journal of cell science* **133**, doi:10.1242/jcs.241794 (2020).
- 1053 122 McCarthy, K. J. The Basement Membrane Proteoglycans Perlecan and Agrin: Something Old,
1054 Something New. *Current topics in membranes* **76**, 255-303, doi:10.1016/bs.ctm.2015.09.001 (2015).
- 1055 123 Greenbaum, L., Alkelai, A., Zozulinsky, P., Kohn, Y. & Lerer, B. Support for association of HSPG2 with
1056 tardive dyskinesia in Caucasian populations. *The pharmacogenomics journal* **12**, 513-520,
1057 doi:10.1038/tpj.2011.32 (2012).
- 1058 124 Li, L. *et al.* Genetic polymorphisms in collagen-related genes are associated with pelvic organ
1059 prolapse. *Menopause (New York, N. Y.)* **27**, 223-229, doi:10.1097/gme.0000000000001448 (2020).
- 1060 125 Fico, A., Maina, F. & Dono, R. Fine-tuning of cell signaling by glypicans. *Cell Mol Life Sci* **68**, 923-929,
1061 doi:10.1007/s00018-007-7471-6 (2011).
- 1062 126 Topaloudi, A. *et al.* Myasthenia gravis genome-wide association study implicates AGRN as a risk
1063 locus. *Journal of medical genetics*, doi:10.1136/jmedgenet-2021-107953 (2021).
- 1064 127 Rygh, C. B. *et al.* Image-based assessment of microvascular function and structure in collagen XV-
1065 and XVIII-deficient mice. *The Journal of physiology* **592**, 325-336, doi:10.1113/jphysiol.2013.263574
1066 (2014).
- 1067 128 Sierksma, A. *et al.* Novel Alzheimer risk genes determine the microglia response to amyloid- β but not
1068 to TAU pathology. *EMBO molecular medicine* **12**, e10606, doi:10.15252/emmm.201910606 (2020).
- 1069 129 Jen, Y. H., Musacchio, M. & Lander, A. D. Glypican-1 controls brain size through regulation of fibroblast
1070 growth factor signaling in early neurogenesis. *Neural development* **4**, 33, doi:10.1186/1749-8104-4-
1071 33 (2009).
- 1072 130 Chung, H., Multhaupt, H. A., Oh, E. S. & Couchman, J. R. Minireview: Syndecans and their crucial
1073 roles during tissue regeneration. *FEBS letters* **590**, 2408-2417, doi:10.1002/1873-3468.12280 (2016).
- 1074 131 Hong, H. *et al.* Up-regulation of syndecan-2 in proximal colon correlates with acute inflammation.
1075 *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*,
1076 fj201900561R, doi:10.1096/fj.201900561R (2019).
- 1077 132 Tsoyi, K. *et al.* Syndecan-2 Attenuates Radiation-induced Pulmonary Fibrosis and Inhibits Fibroblast
1078 Activation by Regulating PI3K/Akt/ROCK Pathway via CD148. *American journal of respiratory cell and*
1079 *molecular biology* **58**, 208-215, doi:10.1165/rcmb.2017-0088OC (2018).
- 1080 133 Stacey, D., Ciobanu, L. G. & Baune, B. T. A systematic review on the association between
1081 inflammatory genes and cognitive decline in non-demented elderly individuals. *European*

- 1082 *neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology* **27**,
1083 568-588, doi:10.1016/j.euroneuro.2015.12.017 (2017).
- 1084 134 Echtermeyer, F. *et al.* Delayed wound repair and impaired angiogenesis in mice lacking syndecan-4.
1085 *The Journal of clinical investigation* **107**, R9-r14, doi:10.1172/jci10559 (2001).
- 1086 135 Sivasami, P. *et al.* Adipose tissue loss and lipodystrophy in xylosyltransferase II deficient mice.
1087 *International journal of obesity (2005)* **43**, 1783-1794, doi:10.1038/s41366-019-0324-1 (2019).
- 1088 136 Afratis, N. A. *et al.* Syndecans - key regulators of cell signaling and biological functions. *The FEBS*
1089 *journal* **284**, 27-41, doi:10.1111/febs.13940 (2017).
- 1090 137 Agere, S. A., Kim, E. Y., Akhtar, N. & Ahmed, S. Syndecans in chronic inflammatory and autoimmune
1091 diseases: Pathological insights and therapeutic opportunities. *Journal of cellular physiology* **233**, 6346-
1092 6358, doi:10.1002/jcp.26388 (2018).
- 1093 138 Gopal, S. Syndecans in Inflammation at a Glance. *Frontiers in immunology* **11**, 227,
1094 doi:10.3389/fimmu.2020.00227 (2020).
- 1095 139 Stepp, M. A., Pal-Ghosh, S., Tadvalkar, G. & Pajoohesh-Ganji, A. Syndecan-1 and Its Expanding List
1096 of Contacts. *Advances in wound care* **4**, 235-249, doi:10.1089/wound.2014.0555 (2015).
- 1097 140 Mizumoto, S., Yamada, S. & Sugahara, K. Human genetic disorders and knockout mice deficient in
1098 glycosaminoglycan. *BioMed research international* **2014**, 495764, doi:10.1155/2014/495764 (2014).
- 1099 141 Hayes, A. J. & Melrose, J. Aggrecan, the Primary Weight-Bearing Cartilage Proteoglycan, Has
1100 Context-Dependent, Cell-Directive Properties in Embryonic Development and Neurogenesis:
1101 Aggrecan Glycan Side Chain Modifications Convey Interactive Biodiversity. *Biomolecules* **10**, 1244,
1102 doi:10.3390/biom10091244 (2020).
- 1103 142 Lauing, K. L. *et al.* Aggrecan is required for growth plate cytoarchitecture and differentiation.
1104 *Developmental biology* **396**, 224-236, doi:10.1016/j.ydbio.2014.10.005 (2014).
- 1105 143 Ponighaus, C. *et al.* Human xylosyltransferase II is involved in the biosynthesis of the uniform
1106 tetrasaccharide linkage region in chondroitin sulfate and heparan sulfate proteoglycans. *The Journal*
1107 *of biological chemistry* **282**, 5201-5206, doi:10.1074/jbc.M611665200 (2007).
- 1108 144 Halper, J. Proteoglycans and diseases of soft tissues. *Advances in experimental medicine and biology*
1109 **802**, 49-58, doi:10.1007/978-94-007-7893-1_4 (2014).
- 1110 145 Gulberti, S. *et al.* Phosphorylation and sulfation of oligosaccharide substrates critically influence the
1111 activity of human beta1,4-galactosyltransferase 7 (GalT-I) and beta1,3-glucuronosyltransferase I
1112 (GlcAT-I) involved in the biosynthesis of the glycosaminoglycan-protein linkage region of
1113 proteoglycans. *The Journal of biological chemistry* **280**, 1417-1425, doi:10.1074/jbc.M411552200
1114 (2005).
- 1115 146 Klein, J. A., Meng, L. & Zaia, J. Deep Sequencing of Complex Proteoglycans: A Novel Strategy for
1116 High Coverage and Site-specific Identification of Glycosaminoglycan-linked Peptides. *Mol Cell*
1117 *Proteomics* **17**, 1578-1590, doi:10.1074/mcp.RA118.000766 (2018).
- 1118 147 Condac, E. *et al.* Polycystic disease caused by deficiency in xylosyltransferase 2, an initiating enzyme
1119 of glycosaminoglycan biosynthesis. *Proceedings of the National Academy of Sciences of the United*
1120 *States of America* **104**, 9416-9421, doi:10.1073/pnas.0700908104 (2007).
- 1121 148 Tsutsui, Y., Ramakrishnan, B. & Qasba, P. K. Crystal structures of beta-1,4-galactosyltransferase 7
1122 enzyme reveal conformational changes and substrate binding. *The Journal of biological chemistry*
1123 **288**, 31963-31970, doi:10.1074/jbc.M113.509984 (2013).
- 1124 149 Liu, X. *et al.* Inactivation of Fam20b in the neural crest-derived mesenchyme of mouse causes multiple
1125 craniofacial defects. *European journal of oral sciences* **126**, 433-436, doi:10.1111/eos.12563 (2018).
- 1126 150 Vogel, P. *et al.* Amelogenesis imperfecta and other biomineralization defects in Fam20a and Fam20c
1127 null mice. *Veterinary pathology* **49**, 998-1017, doi:10.1177/0300985812453177 (2012).
- 1128 151 Huber, C. *et al.* Identification of CANT1 mutations in Desbuquois dysplasia. *American journal of human*
1129 *genetics* **85**, 706-710, doi:10.1016/j.ajhg.2009.10.001 (2009).
- 1130 152 Liu, J., Xu, W., Li, S., Sun, R. & Cheng, W. Multi-omics analysis of tumor mutational burden combined
1131 with prognostic assessment in epithelial ovarian cancer based on TCGA database. *International*
1132 *journal of medical sciences* **17**, 3200-3213, doi:10.7150/ijms.50491 (2020).
- 1133 153 Izumikawa, T. *et al.* GlcUAbeta1-3Galbeta1-3Galbeta1-4Xyl(2-O-phosphate) is the preferred
1134 substrate for chondroitin N-acetylgalactosaminyltransferase-1. *The Journal of biological chemistry*
1135 **290**, 5438-5448, doi:10.1074/jbc.M114.603266 (2015).

- 1136 154 Orellana, A., Moraga, C., Araya, M. & Moreno, A. Overview of Nucleotide Sugar Transporter Gene
1137 Family Functions Across Multiple Species. *Journal of molecular biology* **428**, 3150-3165,
1138 doi:10.1016/j.jmb.2016.05.021 (2016).
- 1139 155 Parker, J. L. & Newstead, S. Gateway to the Golgi: molecular mechanisms of nucleotide sugar
1140 transporters. *Current opinion in structural biology* **57**, 127-134, doi:10.1016/j.sbi.2019.03.019 (2019).
- 1141 156 Anthony, S., Munk, R., Skakun, W. & Masini, M. Multiple epiphyseal dysplasia. *The Journal of the*
1142 *American Academy of Orthopaedic Surgeons* **23**, 164-172, doi:10.5435/jaaos-d-13-00173 (2015).
- 1143 157 Winawer, M. R. *et al.* Somatic SLC35A2 variants in the brain are associated with intractable neocortical
1144 epilepsy. *Annals of neurology* **83**, 1133-1146, doi:10.1002/ana.25243 (2018).
- 1145 158 Pacifici, M. The pathogenic roles of heparan sulfate deficiency in hereditary multiple exostoses. *Matrix*
1146 *Biol* **71-72**, 28-39, doi:10.1016/j.matbio.2017.12.011 (2018).
- 1147 159 Debarnot, C. *et al.* Substrate binding mode and catalytic mechanism of human heparan sulfate d-
1148 glucuronyl C5 epimerase. *Proceedings of the National Academy of Sciences of the United States of*
1149 *America* **116**, 6760-6765, doi:10.1073/pnas.1818333116 (2019).
- 1150 160 Dou, W., Xu, Y., Pagadala, V., Pedersen, L. C. & Liu, J. Role of Deacetylase Activity of N-
1151 Deacetylase/N-Sulfotransferase 1 in Forming N-Sulfated Domain in Heparan Sulfate. *The Journal of*
1152 *biological chemistry* **290**, 20427-20437, doi:10.1074/jbc.M115.664409 (2015).
- 1153 161 Habuchi, H. *et al.* The occurrence of three isoforms of heparan sulfate 6-O-sulfotransferase having
1154 different specificities for hexuronic acid adjacent to the targeted N-sulfoglucosamine. *The Journal of*
1155 *biological chemistry* **275**, 2859-2868, doi:10.1074/jbc.275.4.2859 (2000).
- 1156 162 Jemth, P. *et al.* Oligosaccharide library-based assessment of heparan sulfate 6-O-sulfotransferase
1157 substrate specificity. *The Journal of biological chemistry* **278**, 24371-24376,
1158 doi:10.1074/jbc.M212155200 (2003).
- 1159 163 Sheng, J., Liu, R., Xu, Y. & Liu, J. The dominating role of N-deacetylase/N-sulfotransferase 1 in forming
1160 domain structures in heparan sulfate. *The Journal of biological chemistry* **286**, 19768-19776,
1161 doi:10.1074/jbc.M111.224311 (2011).
- 1162 164 Kjellen, L. Glucosaminyl N-deacetylase/N-sulphotransferases in heparan sulphate biosynthesis and
1163 biology. *Biochemical Society transactions* **31**, 340-342, doi:10.1042/bst0310340 (2003).
- 1164 165 Billings, P. C. & Pacifici, M. Interactions of signaling proteins, growth factors and other proteins with
1165 heparan sulfate: mechanisms and mysteries. *Connective tissue research* **56**, 272-280,
1166 doi:10.3109/03008207.2015.1045066 (2015).
- 1167 166 Reuter, M. S. *et al.* NDST1 missense mutations in autosomal recessive intellectual disability. *American*
1168 *journal of medical genetics. Part A* **164a**, 2753-2763, doi:10.1002/ajmg.a.36723 (2014).
- 1169 167 Takahashi, I. *et al.* Important role of heparan sulfate in postnatal islet growth and insulin secretion.
1170 *Biochem Biophys Res Commun* **383**, 113-118, doi:10.1016/j.bbrc.2009.03.140 (2009).
- 1171 168 Kunnas, T., Solakivi, T., Määttä, K. & Nikkari, S. T. Glucuronic Acid Epimerase (GLCE) Variant
1172 rs3865014 (A>G) Is Associated with BMI, Blood Hemoglobin, Hypertension, and Cerebrovascular
1173 Events, the TAMRISK Study. *Annals of human genetics* **80**, 332-335, doi:10.1111/ahg.12166 (2016).
- 1174 169 Lee, H. *et al.* Whole Genome Analysis of the Red-Crowned Crane Provides Insight into Avian
1175 Longevity. *Molecules and cells* **43**, 86-95, doi:10.14348/molcells.2019.0190 (2020).
- 1176 170 Borjigin, J. *et al.* Diurnal pineal 3-O-sulphotransferase 2 expression controlled by beta-adrenergic
1177 repression. *The Journal of biological chemistry* **278**, 16315-16319, doi:10.1074/jbc.M300828200
1178 (2003).
- 1179 171 Vanpouille, C. *et al.* The heparin/heparan sulfate sequence that interacts with cyclophilin B contains a
1180 3-O-sulfated N-unsubstituted glucosamine residue. *The Journal of biological chemistry* **282**, 24416-
1181 24429, doi:M701835200 [pii]
1182 10.1074/jbc.M701835200 (2007).
- 1183 172 Rönnerberg, E., Melo, F. R. & Pejler, G. Mast cell proteoglycans. *The journal of histochemistry and*
1184 *cytochemistry : official journal of the Histochemistry Society* **60**, 950-962,
1185 doi:10.1369/0022155412458927 (2012).
- 1186 173 Nguyen, N. T. *et al.* Genetic and enzymatic characterization of 3-O-sulfotransferase SNPs associated
1187 with Plasmodium falciparum parasitaemia. *Glycobiology* **28**, 534-541, doi:10.1093/glycob/cwy038
1188 (2018).
- 1189 174 Osorio, S., Rivillas, N. D. & Martinez, J. A. Urofacial (ochoa) syndrome: A literature review. *Journal of*
1190 *pediatric urology* **17**, 246-254, doi:10.1016/j.jpuro.2021.01.017 (2021).

- 1191 175 Woolf, A. S., Stuart, H. M. & Newman, W. G. Genetics of human congenital urinary bladder disease.
1192 *Pediatric nephrology (Berlin, Germany)* **29**, 353-360, doi:10.1007/s00467-013-2472-1 (2014).
- 1193 176 Chen, H., Wang, T., Yang, J., Huang, S. & Zeng, P. Improved Detection of Potentially Pleiotropic
1194 Genes in Coronary Artery Disease and Chronic Kidney Disease Using GWAS Summary Statistics.
1195 *Frontiers in genetics* **11**, 592461, doi:10.3389/fgene.2020.592461 (2020).
- 1196 177 Deligny, A. *et al.* NDST2 (N-Deacetylase/N-Sulfotransferase-2) Enzyme Regulates Heparan Sulfate
1197 Chain Length. *The Journal of biological chemistry* **291**, 18600-18607, doi:10.1074/jbc.M116.744433
1198 (2016).
- 1199 178 Huang, Y. C. *et al.* Genome-wide association study of diabetic retinopathy in a Taiwanese population.
1200 *Ophthalmology* **118**, 642-648, doi:10.1016/j.ophtha.2010.07.020 (2011).
- 1201 179 Espinosa, A. *et al.* Exploring Genetic Associations of Alzheimer's Disease Loci With Mild Cognitive
1202 Impairment Neurocognitive Endophenotypes. *Frontiers in aging neuroscience* **10**, 340,
1203 doi:10.3389/fnagi.2018.00340 (2018).
- 1204 180 Shworak, N. W., Kobayashi, T., de Agostini, A. & Smits, N. C. Anticoagulant heparan sulfate to not
1205 clot--or not? *Progress in molecular biology and translational science* **93**, 153-178, doi:10.1016/s1877-
1206 1173(10)93008-1 (2010).
- 1207 181 Sepulveda-Diaz, J. E. *et al.* HS3ST2 expression is critical for the abnormal phosphorylation of tau in
1208 Alzheimer's disease-related tau pathology. *Brain : a journal of neurology* **138**, 1339-1354,
1209 doi:10.1093/brain/awv056 (2015).
- 1210 182 Atkinson, A., Garnier, S., Afridi, S., Fumoux, F. & Rihet, P. Genetic variations in genes involved in
1211 heparan sulphate biosynthesis are associated with Plasmodium falciparum parasitaemia: a familial
1212 study in Burkina Faso. *Malaria journal* **11**, 108, doi:10.1186/1475-2875-11-108 (2012).
- 1213 183 Mackinnon, M. J. *et al.* Environmental Correlation Analysis for Genes Associated with Protection
1214 against Malaria. *Molecular biology and evolution* **33**, 1188-1204, doi:10.1093/molbev/msw004 (2016).
- 1215 184 Howard, S. R. *et al.* HS6ST1 Insufficiency Causes Self-Limited Delayed Puberty in Contrast With
1216 Other GnRH Deficiency Genes. *The Journal of clinical endocrinology and metabolism* **103**, 3420-3429,
1217 doi:10.1210/jc.2018-00646 (2018).
- 1218 185 Hayashi, S. *et al.* Comprehensive investigation of CASK mutations and other genetic etiologies in 41
1219 patients with intellectual disability and microcephaly with pontine and cerebellar hypoplasia (MICPCH).
1220 *PloS one* **12**, e0181791, doi:10.1371/journal.pone.0181791 (2017).
- 1221 186 Poon, I. K. *et al.* Mice deficient in heparanase exhibit impaired dendritic cell migration and reduced
1222 airway inflammation. *European journal of immunology* **44**, 1016-1030, doi:10.1002/eji.201343645
1223 (2014).
- 1224 187 Holst, C. R. *et al.* Secreted sulfatases Sulf1 and Sulf2 have overlapping yet essential roles in mouse
1225 neonatal survival. *PloS one* **2**, e575, doi:10.1371/journal.pone.0000575 (2007).
- 1226 188 Hassing, H. C. *et al.* SULF2 strongly predisposes to fasting and postprandial triglycerides in patients
1227 with obesity and type 2 diabetes mellitus. *Obesity (Silver Spring, Md.)* **22**, 1309-1316,
1228 doi:10.1002/oby.20682 (2014).
- 1229 189 Matikainen, N. *et al.* Genetic variation in SULF2 is associated with postprandial clearance of
1230 triglyceride-rich remnant particles and triglyceride levels in healthy subjects. *PloS one* **8**, e79473,
1231 doi:10.1371/journal.pone.0079473 (2013).
- 1232 190 Duchez, S. *et al.* Glycotranscriptome study reveals an enzymatic switch modulating
1233 glycosaminoglycan synthesis during B-cell development and activation. *European journal of*
1234 *immunology* **41**, 3632-3644, doi:10.1002/eji.201140865 (2011).
- 1235 191 Mizumoto, S., Yamada, S. & Sugahara, K. Mutations in Biosynthetic Enzymes for the Protein Linker
1236 Region of Chondroitin/Dermatan/Heparan Sulfate Cause Skeletal and Skin Dysplasias. *BioMed*
1237 *research international* **2015**, 861752, doi:10.1155/2015/861752 (2015).
- 1238 192 Esko, J. D. & Selleck, S. B. Order out of chaos: assembly of ligand binding sites in heparan sulfate.
1239 *Annual review of biochemistry* **71**, 435-471, doi:10.1146/annurev.biochem.71.110601.135458 (2002).
- 1240 193 Gesslbauer, B., Rek, A., Falsone, F., Rajkovic, E. & Kungl, A. J. Proteoglycanomics: tools to unravel
1241 the biological function of glycosaminoglycans. *Proteomics* **7**, 2870-2880, doi:10.1002/pmic.200700176
1242 (2007).
- 1243 194 Aikawa, J., Grobe, K., Tsujimoto, M. & Esko, J. D. Multiple isozymes of heparan sulfate/heparin
1244 GlcNAc N-deacetylase/GlcN N-sulfotransferase. Structure and activity of the fourth member, NDST4.
1245 *The Journal of biological chemistry* **276**, 5876-5882, doi:10.1074/jbc.M009606200 (2001).
- 1246 195 Habuchi, H. *et al.* Biosynthesis of heparan sulphate with diverse structures and functions: two
1247 alternatively spliced forms of human heparan sulphate 6-O-sulphotransferase-2 having different

- 1248 expression patterns and properties. *The Biochemical journal* **371**, 131-142, doi:10.1042/bj20021259
1249 (2003).
- 1250 196 Lawrence, R. *et al.* The principal neuronal gD-type 3-O-sulfotransferases and their products in central
1251 and peripheral nervous system tissues. *Matrix Biol* **26**, 442-455, doi:10.1016/j.matbio.2007.03.002
1252 (2007).
- 1253 197 Li, Y. J. *et al.* Characterization of heparan sulfate N-deacetylase/N-sulfotransferase isoform 4 using
1254 synthetic oligosaccharide substrates. *Biochimica et biophysica acta. General subjects* **1862**, 547-556,
1255 doi:10.1016/j.bbagen.2017.11.016 (2018).
- 1256 198 Mochizuki, H. *et al.* Characterization of a heparan sulfate 3-O-sulfotransferase-5, an enzyme
1257 synthesizing a tetrasulfated disaccharide. *The Journal of biological chemistry* **278**, 26780-26787,
1258 doi:10.1074/jbc.M301861200 (2003).
- 1259 199 Sheng, J., Xu, Y., Dulaney, S. B., Huang, X. & Liu, J. Uncovering biphasic catalytic mode of C5-
1260 epimerase in heparan sulfate biosynthesis. *The Journal of biological chemistry* **287**, 20996-21002,
1261 doi:10.1074/jbc.M112.359885 (2012).
- 1262 200 Rudd, T. R. & Yates, E. A. A highly efficient tree structure for the biosynthesis of heparan sulfate
1263 accounts for the commonly observed disaccharides and suggests a mechanism for domain synthesis.
1264 *Molecular bioSystems* **8**, 1499-1506, doi:10.1039/c2mb25019e (2012).
- 1265